var title_f28_56_29568="CNS lymphoma subretinal pigment epithelium infiltrates";
var content_f28_56_29568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Characteristic fundus findings of intraocular-central nervous system lymphomalymphomatous subretinal pigment epithelial (subRPE) infiltrates, retinochoroiditis, and vasculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fundus photograph of the right eye shows characteristic subretinal pigment epithelium yellow infiltrates.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology 1999; 106:1805. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29568=[""].join("\n");
var outline_f28_56_29568=null;
var title_f28_56_29569="Tibial bowing in osteomalacia";
var content_f28_56_29569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79529%7EENDO%2F57357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79529%7EENDO%2F57357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tibial bowing in osteomalacia: Radiographic findings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tibial shortening and bowing in a man with vitamin D resistant rickets. A surgical osteotomy was performed to correct the tibial bending (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of CJ Menkes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coxa profunda abnormality in osteomalacia: Radiographic findings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone film in a patient with vitamin D resistant rickets showing hip deformity with coxa profunda (in which the femoral head comes deeply into the pelvis), coxa vara (in which the angle between the femoral neck and the femoral shaft is diminished) (arrow), and rods representing surgical treatment of pathologic fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of CJ Menkes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29569=[""].join("\n");
var outline_f28_56_29569=null;
var title_f28_56_29570="Povidone iodine (ophthalmic): Drug information";
var content_f28_56_29570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Povidone iodine (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betadine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9509769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiseptic, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9505452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Antiseptic:",
"     </b>",
"     Ophthalmic solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Eyelids: Apply to area with a sterile cotton-tipped applicator; repeat once",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Periocular region: Apply in a circular expanding pattern until the entire field is covered; repeat 3 times",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular irrigation: Irrigate the cornea, conjunctiva, and palpebral fornices; leave for 2 minutes, then rinse with sterile saline",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9505453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betadine&reg;: 5% (30 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9603191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eyelids: Saturate sterile cotton-tipped applicator to prep lashes and lid margins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Periocular region: Saturate sterile prep sponge for periocular region and use circular motions to cover area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular surface irrigation: Use a sterile bulb syringe. Separate the lids and irrigate the cornea, conjunctiva, and palpebral fornices. Leave on for 2 minutes, then flush with sterile saline solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9505366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prepping the periocular region (lids, brows, and cheeks) and irrigation of the ocular surface",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Betadine&reg; may be confused with Betagan&reg;, betaine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9505427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Also refer to Iodine monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Edema, irritation, pruritus, rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9505372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9505381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid disorders.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Transient hypothyroidism in the newborn has been reported following topical or vaginal use prior to delivery (refer to Iodine monograph for additional information). The amount absorbed following ophthalmic administration is not known.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9887314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9887315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount absorbed following ophthalmic administration is not known. Also refer to Iodine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Betadine Ophthalmic Prep Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (30 mL): $13.45",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9505434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Povidone-iodine is known to be a powerful broad spectrum germicidal agent effective against a wide range of bacteria, viruses, fungi, protozoa, and spores.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9909 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29570=[""].join("\n");
var outline_f28_56_29570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505339\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9509769\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505452\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505453\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505488\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505365\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9603191\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505366\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505335\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505427\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505372\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505381\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299927\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505430\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505367\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887313\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887314\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887315\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322432\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505434\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9909\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9909|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/35/28213?source=related_link\">",
"      Povidone iodine (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_56_29571="Chest x-rays with and without thymic shadows";
var content_f28_56_29571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest x-rays with and without thymic shadows",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 638px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top chest radiograph shows a normal thymic shadow. The bottom radiograph shows absence of the thymic shadow in an infant with severe combined immunodeficiency (SCID).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Pierre Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29571=[""].join("\n");
var outline_f28_56_29571=null;
var title_f28_56_29572="Polysaccharide-iron complex: Drug information";
var content_f28_56_29572=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polysaccharide-iron complex: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/49/39700?source=see_link\">",
"    see \"Polysaccharide-iron complex: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11392046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrex&trade; 150 Plus [OTC];",
"     </li>",
"     <li>",
"      Ferrex&trade; 150 [OTC];",
"     </li>",
"     <li>",
"      Nu-Iron&reg; 150 [OTC];",
"     </li>",
"     <li>",
"      Poly-Iron 150 [OTC];",
"     </li>",
"     <li>",
"      ProFe [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake: Dose is RDA presented as elemental iron unless otherwise noted:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-50 years: Males: 8 mg/day; Females: 18 mg/day; Pregnant females: 27 mg/day; Lactating females: 9 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;50 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Iron deficiency (prevention/treatment):",
"     </b>",
"     Oral: 150-300 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake: Dose is RDA presented as elemental iron unless otherwise noted:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0-6 months: 0.27 mg/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 11 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 7 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: Males: 11 mg/day; Females: 15 mg/day; Pregnant females: 27 mg/day; Lactating females: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Iron deficiency (prevention/treatment):",
"     </b>",
"     Oral: Children &ge;6 years:  50-100 mg/day; may be given in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferrex&trade; 150: Elemental iron 150 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferrex&trade; 150 Plus: Elemental iron 150 mg (50 mg as ferrous asparto glycinate) [contains ascorbic acid 50 mg and succinic acid 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nu-Iron&reg; 150: Elemental iron 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Poly-Iron 150: Elemental iron 150 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProFe: Elemental iron 180 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron-deficiency anemias",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F211227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Niferex may be confused with Nephrox&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Stomach cramping, constipation, nausea, vomiting, dark stools, GI irritation, epigastric pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Heartburn, diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Discolored urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Staining of teeth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Contact irritation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11392044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Iron Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Iron Salts may decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6789298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6789300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6789301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is normally found in breast milk. Breast milk or iron fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6789323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F211211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ferrex 150 Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150-50-50 mg (90): $114.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (FerUS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $17.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Nu-Iron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $51.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Poly-Iron 150 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (100): $27.95",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(1):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29572/abstract-text/18591330/pubmed\" id=\"18591330\" target=\"_blank\">",
"        18591330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2000, 14(5):1061-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29572/abstract-text/11005034/pubmed\" id=\"11005034\" target=\"_blank\">",
"        11005034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Nutrition During Lactation.&rdquo; Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board Institute of Medicine, National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-3):1-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29572/abstract-text/9563847/pubmed\" id=\"9563847\" target=\"_blank\">",
"        9563847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Routine Iron Supplementation During Pregnancy. Review Article. US Preventive Services Task Force,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(23):2848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29572/abstract-text/8133626/pubmed\" id=\"8133626\" target=\"_blank\">",
"        8133626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10222 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-0ACB48A304-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29572=[""].join("\n");
var outline_f28_56_29572=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392046\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211213\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211222\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211214\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211218\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211215\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211207\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211198\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211208\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211227\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211220\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11392044\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299906\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222429\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789298\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789300\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789301\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789323\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211211\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10222\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10222|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/49/39700?source=related_link\">",
"      Polysaccharide-iron complex: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_56_29573="Natriuretic peptide measurement in non-heart failure settings";
var content_f28_56_29573=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natriuretic peptide measurement in non-heart failure settings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29573/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29573/contributors\">",
"     Horng H Chen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29573/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29573/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29573/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29573/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29573/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29573/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/56/29573/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27656580\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natriuretic peptide system impacts salt and water handling and pressure regulation and may influence myocardial structure and function.",
"   </p>",
"   <p>",
"    Brain natriuretic peptide (BNP) is a natriuretic hormone initially identified in the brain but released primarily from the heart, particularly the ventricles. Cleavage of the prohormone proBNP produces biologically active 32 amino acid BNP as well as biologically inert 76 amino acid N-terminal pro-BNP (NT-proBNP).",
"   </p>",
"   <p>",
"    Atrial natriuretic peptide (ANP) is a hormone that is released from myocardial cells in the atria and in some cases the ventricles in response to volume expansion and possibly increased wall stress [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/1\">",
"     1",
"    </a>",
"    ]. ANP circulates primarily as a 28 amino acid polypeptide, consisting of amino acids 99 to 126 from the C-terminal end of its prohormone, pro-ANP.",
"   </p>",
"   <p>",
"    The release of both ANP and BNP is increased in heart failure (HF), as ventricular cells are recruited to secrete both ANP and BNP in response to the high ventricular filling pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/2\">",
"     2",
"    </a>",
"    ]. The plasma concentrations of both hormones are increased in patients with asymptomatic and symptomatic left ventricular dysfunction, permitting their use in diagnosis (",
"    <a class=\"graphic graphic_figure graphicRef55557 \" href=\"UTD.htm?20/13/20701\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Natriuretic peptide levels are elevated in some patients with coronary heart disease, valvular heart disease, constrictive pericarditis, pulmonary hypertension, and sepsis. The diagnostic and prognostic value of measuring plasma BNP and N-terminal pro-BNP (NT-proBNP) in asymptomatic individuals and patients with such non-heart failure conditions is discussed here. While the discussion here will focus on patients without overt heart failure, BNP or NT-proBNP elevations in some of these settings may be a sign of undiagnosed heart failure.",
"   </p>",
"   <p>",
"    The diagnostic and prognostic value of measuring plasma BNP, NT-proBNP, and mid-regional pro-atrial natriuretic peptide (MR-proANP) in patients with heart failure and the possible therapeutic role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    (recombinant human BNP) in the management of patients with decompensated HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=see_link\">",
"     \"Nesiritide in the treatment of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27939568\">",
"    <span class=\"h1\">",
"     ASSAY INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of variables affect plasma BNP and NT-proBNP levels including the assay used, age (higher normal values with age), sex (higher values in women), and body mass index (lower levels with higher body mass index), and genetic factors. In addition, there is intraindividual and analytic assay variation. These issues are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link&amp;anchor=H3#H3\">",
"     \"Natriuretic peptide measurement in heart failure\", section on 'Assay interpretation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link&amp;anchor=H27939917#H27939917\">",
"     \"Natriuretic peptide measurement in heart failure\", section on 'Obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27939639\">",
"    <span class=\"h1\">",
"     CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27939351\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP and NT-proBNP concentrations are elevated in patients with renal failure. In patients with chronic kidney disease, decreased estimated GFR is associated with increased plasma BNP and even greater elevation in NT-proBNP concentrations. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link&amp;anchor=H22200902#H22200902\">",
"     \"Natriuretic peptide measurement in heart failure\", section on 'Renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27656787\">",
"    <span class=\"h2\">",
"     Predictor of cardiovascular events",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18422045\">",
"    <span class=\"h3\">",
"     Population-based studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP and the N-terminal fragment of pro-ANP (N-proANP) levels are predictors of the development of HF, as well as other cardiovascular events, in asymptomatic patients without HF. This was demonstrated in a prospective evaluation of 3346 participants (mean age 59 years) in the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/3\">",
"     3",
"    </a>",
"    ]. At five years, 119 patients died (3.6 percent) and 79 had a first cardiovascular event (MI, coronary insufficiency, death from coronary heart disease, HF, or stroke; 2.4 percent). Baseline plasma BNP and N-proANP levels above the 80th percentile were both associated with a significant increase in the subsequent development of HF (adjusted hazard ratio [HR] 3.07 and 5.02), as well as less marked increases in all-cause mortality, atrial fibrillation, and stroke or transient ischemic attack.",
"   </p>",
"   <p>",
"    The ability of NT-proBNP to predict cardiovascular events was evaluated in a population-based study of 626 older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/4\">",
"     4",
"    </a>",
"    ]. Individuals with NT-proBNP levels above the 80th percentile (more than 655",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    had, at five year follow-up, a significant increase in mortality compared to those with lower values (adjusted hazard ratio for mortality 1.96 overall and 1.82 after adjusted for left ventricular dysfunction compared to lower values and an absolute unadjusted increase in mortality of 19.5 percent). Among the 537 participants with no prior history of cardiovascular disease, those with NT-proBNP above the 80th percentile had a significantly higher risk of a first major cardiovascular event (adjusted hazard ratio 3.24).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27656794\">",
"    <span class=\"h3\">",
"     Prognosis in ACS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in plasma BNP or NT-proBNP are associated with increased mortality in patients with an acute coronary syndrome (ACS). The prognostic value of plasma BNP and NT-proBNP in this setting is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link&amp;anchor=H19#H19\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\", section on 'Plasma BNP and N-pro-BNP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27656801\">",
"    <span class=\"h3\">",
"     Prognosis in stable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP concentrations have prognostic value in patients with stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a review of 1085 such patients who had plasma BNP measured at baseline and were then prospectively followed for a mean of 2.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/6\">",
"     6",
"    </a>",
"    ]. There was a stepwise decrease in event-free survival across quartiles of plasma BNP. After adjustment for confounders including LVEF, patients in the highest quartile (plasma BNP &gt;100",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    had a significant 6.1-fold increase in risk compared to those in the lowest quartile (plasma BNP &lt;12",
"    <span class=\"nowrap\">",
"     pg/mL);",
"    </span>",
"    the hazard ratio was 4.4 for plasma BNP values &gt;100",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Plasma",
"    N-terminal pro-BNP appears to have equivalent predictive value in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/5\">",
"     5",
"    </a>",
"    ]. The predictive value of NT-proBNP in patients with stable angina was evaluated in a report of 1034 patients who were referred for coronary angiography and then followed for nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/7\">",
"     7",
"    </a>",
"    ]. At follow-up, 288 patients (28 percent) had died. The patients who died had significant higher NT-proBNP values at presentation (386 versus 120",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    Patients with NT-proBNP values in the highest quartile were older, had a lower LVEF, and were more likely to have diabetes and a prior MI. In a multivariable model, these patients had a hazard ratio for death of 2.4 compared to those in the lowest quartile.",
"   </p>",
"   <p>",
"    Similar findings were noted in a review of 1059 patients with chronic stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/8\">",
"     8",
"    </a>",
"    ]. At a median of 3.6 years, the five year mortality progressively increased from 4.7 percent in patients in the lowest quartile of NT-proBNP to 7.8 percent, 11.4 percent, and 32.7 percent in the second, third, and highest quintiles, respectively (adjusted hazards ratio 6.0, 95% CI 1.6-23 for the highest compared to lowest quintile). A similar prognostic value was noted for cardiovascular mortality and for patients with New York Heart Association functional class I and II (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). However, as in the previous study, patients in the highest NT-proBNP quartile had other major comorbidities including highest rates of diabetes, atrial fibrillation, and NYHA class III or IV (18.5 versus 0.8 percent in the lowest quartile).",
"   </p>",
"   <p>",
"    Further studies are required to determine if measurement of BNP or NT-proBNP has clinical utility in the management of patients with stable angina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18422007\">",
"    <span class=\"h3\">",
"     Perioperative complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative elevations in plasma BNP are associated with a significantly increased risk of adverse cardiovascular events in the perioperative period. In a 2009 meta-analysis that included seven studies of 2841 patients who had a serum BNP measurement before noncardiac surgery, there was a statistically significant association between a preoperative elevation in serum BNP and the cardiovascular outcomes of death, cardiac death, and nonfatal myocardial infarction at 30 days (adjusted odds ratio 19.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/9\">",
"     9",
"    </a>",
"    ]. A 2011 meta-analysis that evaluated post-operative mortality at six months or later came to a similar conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16051290\">",
"    <span class=\"h2\">",
"     Valvular heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential prognostic value of natriuretic peptide measurement in patients with valvular heart disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link&amp;anchor=H18#H18\">",
"     \"Indications for valve replacement in aortic stenosis in adults\", section on 'Possible role of brain natriuretic peptide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=see_link\">",
"     \"Low gradient aortic stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link&amp;anchor=H14009091#H14009091\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Natriuretic peptide levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27657164\">",
"    <span class=\"h2\">",
"     Constrictive pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic assessment is often required to distinguish constrictive pericarditis from restrictive cardiomyopathy. However, wall stretch is increased in the latter but minimized in the former by the thickened pericardium. This difference suggests that measurement of plasma BNP might have value in distinguishing between these two disorders.",
"   </p>",
"   <p>",
"    This hypothesis was evaluated in a report of six patients with constrictive pericarditis and five with restrictive cardiomyopathy in which plasma BNP was markedly elevated in patients with restrictive cardiomyopathy but just above normal in those with constrictive pericarditis (825 versus 128",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/11\">",
"     11",
"    </a>",
"    ]. These intriguing observations need to be confirmed in a larger number of patients to determine the accuracy of BNP testing in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link&amp;anchor=H740032#H740032\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\", section on 'Plasma BNP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27657061\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP concentrations are elevated in patients with primary or secondary pulmonary hypertension. In such patients, they correlate positively with right atrial pressure, mean pulmonary artery pressure, pulmonary vascular resistance, and RV mass, and inversely with cardiac index [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Using elevated plasma BNP to determine the cause of dyspnea in patients with pulmonary hypertension may be misleading since lung disease is responsible for the dyspnea unless the patient has secondary pulmonary hypertension due to left heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27657068\">",
"    <span class=\"h2\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data supporting the diagnostic accuracy of natriuretic peptides are largely derived from emergency department patients. The role of BNP and NT-proBNP in other settings, in particular the intensive care unit (ICU), is less well established.",
"   </p>",
"   <p>",
"    An observational series from a single center suggests that in an ICU setting, patients with a diagnosis of sepsis are as likely to have elevated BNP and NT-proBNP levels as patients with decompensated HF [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29573/abstract/14\">",
"     14",
"    </a>",
"    ]. Among 249 consecutive patients, 24 were diagnosed with sepsis and 51 with decompensated HF. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BNP and NT-proBNP levels were similar in both groups (572 versus 581",
"      <span class=\"nowrap\">",
"       ng/L,",
"      </span>",
"      and 6526 versus 4300",
"      <span class=\"nowrap\">",
"       ng/L",
"      </span>",
"      for sepsis and HF patients, respectively).",
"     </li>",
"     <li>",
"      Patients with decompensated HF had a significantly higher mean pulmonary artery capillary wedge pressure (22 versus 16 mmHg) and a lower mean cardiac index (2.2 versus 4.6",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      per m2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in a heterogeneous population of critically ill patients, levels of natriuretic peptides were similar in patients with sepsis and those with decompensated HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18421923\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma brain natriuretic peptide (BNP) and N-terminal pro-BNP levels (NT-proBNP) are elevated in patients with heart failure as well as in some patients without overt heart failure with a variety of conditions including renal failure, coronary heart disease, valvular heart disease, constrictive pericarditis, pulmonary hypertension, and sepsis. (See",
"      <a class=\"local\" href=\"#H27656580\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated BNP or NT-proBNP levels predict an increased risk of cardiovascular events in various patient populations including those with and without prior symptomatic cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H27656787\">",
"       'Predictor of cardiovascular events'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/1\">",
"      Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/2\">",
"      Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/3\">",
"      Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/4\">",
"      Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/5\">",
"      Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006; 47:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/6\">",
"      Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006; 47:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/7\">",
"      Kragelund C, Gr&oslash;nning B, K&oslash;ber L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/8\">",
"      Ndrepepa G, Braun S, Niem&ouml;ller K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 2005; 112:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/9\">",
"      Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol 2009; 54:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/10\">",
"      Lurati Buse GA, Koller MT, Burkhart C, et al. The predictive value of preoperative natriuretic peptide concentrations in adults undergoing surgery: a systematic review and meta-analysis. Anesth Analg 2011; 112:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/11\">",
"      Leya FS, Arab D, Joyal D, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 2005; 45:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/12\">",
"      Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/13\">",
"      Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29573/abstract/14\">",
"      Rudiger A, Gasser S, Fischler M, et al. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006; 34:2140.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17124 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29573=[""].join("\n");
var outline_f28_56_29573=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18421923\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27656580\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27939568\">",
"      ASSAY INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27939639\">",
"      CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27939351\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27656787\">",
"      Predictor of cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18422045\">",
"      - Population-based studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27656794\">",
"      - Prognosis in ACS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27656801\">",
"      - Prognosis in stable angina",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18422007\">",
"      - Perioperative complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16051290\">",
"      Valvular heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27657164\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27657061\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27657068\">",
"      Sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18421923\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/17124\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/17124|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/13/20701\" title=\"figure 1\">",
"      ANP BNP LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/17124|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/14/35047?source=related_link\">",
"      Low gradient aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35701?source=related_link\">",
"      Nesiritide in the treatment of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_56_29574="Membranous VSD short axis color still frame";
var content_f28_56_29574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Membranous VSD short axis color still frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These paired short axis images show a large membranous ventricular septal defect (VSD) (arrow) beneath the septal leaflet of the tricuspid valve. The jet of systolic left-to-right flow across the defect is well demonstrated by Doppler color flow mapping in the left hand panel.",
"    <div class=\"footnotes\">",
"     LA: left atrium; RA: right atrium; RV: right ventricle; LVOT: left ventricular outflow tract; PA: pulmonary artery; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29574=[""].join("\n");
var outline_f28_56_29574=null;
var title_f28_56_29575="Foscarnet: Drug information";
var content_f28_56_29575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Foscarnet: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/11/37044?source=see_link\">",
"    see \"Foscarnet: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/4/24646?source=see_link\">",
"    see \"Foscarnet: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14934198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Foscavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Foscavir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CMV retinitis:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction treatment:",
"     </i>",
"     60 mg/kg/dose every 8 hours for 14-21 days",
"     <b>",
"      or",
"     </b>",
"     90 mg/kg every 12 hours for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance therapy:",
"     </i>",
"     90-120 mg/kg/day as a single daily infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acyclovir-resistant HSV induction treatment:",
"     </b>",
"     I.V.: 40 mg/kg/dose every 8-12 hours for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Therapy of CMV infection in cancer patients (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis:",
"     </i>",
"     60 mg/kg every 8-12 hours for 7 days, followed by 90-120 mg/kg daily until day 100 after HSCT",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pre-emptive treatment:",
"     </i>",
"     60 mg/kg every 12 hours for 14 days; if CMV still detectable, continue with 90 mg/kg daily for 5 days/week for 2 additional weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Treatment:",
"     </i>",
"     90 mg/kg every 12 hours for 2 weeks, followed by 120 mg/kg daily for &ge;2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F174190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/4/24646?source=see_link\">",
"      see \"Foscarnet: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F174171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F174172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See tables.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Induction Dosing of Foscarnet in Patients With Abnormal Renal Function",
"     </caption>",
"     <col width=\"80\">",
"     </col>",
"     <col width=\"105\">",
"     </col>",
"     <col width=\"105\">",
"     </col>",
"     <col width=\"105\">",
"     </col>",
"     <col width=\"105\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         (mL/min/kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         HSV",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         HSV",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         CMV",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         CMV",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Equivalent to 40 mg/kg q12h",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Equivalent to 40 mg/kg q8h",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Equivalent to 60 mg/kg q8h",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Equivalent to 90 mg/kg q12h",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;0.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Not recommended",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Not recommended",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Not recommended",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Not recommended",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;0.4-0.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg/kg every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;0.5-0.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60 mg/kg every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;0.6-0.8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25 mg/kg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40 mg/kg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80 mg/kg every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;0.8-1.0",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mg/kg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         35 mg/kg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg/kg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg/kg every 12 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;1.0-1.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30 mg/kg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30 mg/kg every 8 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45 mg/kg every 8 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         70 mg/kg every 12 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;1.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40 mg/kg every 12 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40 mg/kg every 8 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60 mg/kg every 8 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90 mg/kg every 12 hours",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Maintenance Dosing of Foscarnet in Patients With Abnormal Renal Function",
"     </caption>",
"     <col width=\"110\">",
"     </col>",
"     <col width=\"185\">",
"     </col>",
"     <col width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         (mL/min/kg)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         CMV",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         CMV",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Equivalent to 90 mg/kg q24h",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Equivalent to 120 mg/kg q24h",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;0.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Not recommended",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Not recommended",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;0.4-0.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg/kg every 48 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         65 mg/kg every 48 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;0.5-0.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60 mg/kg every 48 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80 mg/kg every 48 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;0.6-0.8",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80 mg/kg every 48 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         105 mg/kg every 48 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;0.8-1.0",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         65 mg/kg every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;1.0-1.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         70 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90 mg/kg every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;1.4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90 mg/kg every 24 hours",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         120 mg/kg every 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hemodialysis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Foscarnet is highly removed by hemodialysis (up to ~38% in 2.5 hours HD with high-flux membrane)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Doses of 50 mg/kg/dose posthemodialysis have been found to produce similar serum concentrations as doses of 90 mg/kg twice daily in patients with normal renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Doses of 60-90 mg/kg/dose loading dose (posthemodialysis) followed by 45-60 mg/kg/dose posthemodialysis (3 times/week) with the monitoring of weekly plasma concentrations to maintain peak plasma concentrations in the range of 400-800 &mu;Molar have been recommended by some clinicians",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous arteriovenous or venovenous hemodiafiltration effects: Dose as for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [preservative free]: 24 mg/mL (250 mL, 500 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foscavir&reg;: 24 mg/mL (250 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F174151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Foscarnet is administered by intravenous infusion, using an infusion pump, at a rate not exceeding 1 mg/kg/minute. Undiluted (24 mg/mL) solution can be administered without further dilution when using a central venous catheter for infusion. For peripheral vein administration, the solution",
"     <b>",
"      must",
"     </b>",
"     be diluted to a final concentration",
"     <b>",
"      not to exceed",
"     </b>",
"     12 mg/mL. The manufacturer recommends 750-1000 mL of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W be administered prior to first infusion to establish diuresis. With subsequent infusions of 90-120 mg/kg, this volume would be repeated. If the dose were 40-60 mg/kg, then the volume could be reduced to 500 mL. After the first dose, the hydration fluid should be administered concurrently with foscarnet.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F174214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextrose 30%, LR, TPN, and I.V. solutions containing calcium, magnesium, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Aldesleukin, amikacin, aminophylline, ampicillin, aztreonam, cefazolin, cefoxitin, ceftazidime,  cefuroxime, chloramphenicol, cimetidine, clindamycin, dexamethasone sodium phosphate, dopamine, doripenem, erythromycin lactobionate, fluconazole, flucytosine, furosemide, gentamicin, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, metoclopramide, metronidazole, morphine, nafcillin, oxacillin, penicillin G potassium, phenytoin, piperacillin, ranitidine, ticarcillin/clavulanate, tobramycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, diazepam, digoxin, diphenhydramine, dobutamine, droperidol, ganciclovir, haloperidol, leucovorin calcium, midazolam, pentamidine, prochlorperazine edisylate, promethazine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B, ceftriaxone, lorazepam, sulfamethoxazole/trimethoprim, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised persons (eg, with advanced AIDS); treatment of CMV retinitis in persons with HIV",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F174204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other CMV infections (eg, colitis, esophagitis, neurological disease); CMV prophylaxis for cancer patients receiving alemtuzumab therapy or allogeneic stem cell transplant",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (65%), headache (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (16% to 48%), hypocalcemia (15% to 30%), hypomagnesemia (15% to 30%), hypophosphatemia (8% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (47%), diarrhea (30%), vomiting (26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (33%), granulocytopenia (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Abnormal renal function/decreased creatinine clearance (12%; without adequate hydration 33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1% to 5%), edema (1% to 5%), facial edema (1% to 5%), flushing (1% to 5%), hyper-/hypotension (1% to 5%), palpitation (1% to 5%), ECG changes (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Seizures (8% to 10%), anxiety (&ge;5%), confusion (&ge;5%), depression (&ge;5%), dizziness (&ge;5%), fatigue (&ge;5%), hypoesthesia (&ge;5%), malaise (&ge;5%), pain (&ge;5%), aggressiveness (1% to 5%), agitation (1% to 5%), amnesia (1% to 5%), aphasia (1% to 5%), ataxia (1% to 5%), coordination abnormal (1% to 5%), dementia (1% to 5%), EEG abnormal (1% to 5%), hallucination (1% to 5%), insomnia (1% to 5%), meningitis (1% to 5%), nervousness (1% to 5%), somnolence (1% to 5%), stupor (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&ge;5%), erythematous rash (1% to 5%), maculopapular rash (1% to 5%), pruritus (1% to 5%), seborrhea (1% to 5%), skin discoloration (1% to 5%), skin ulceration (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperphosphatemia (6%), acidosis (1% to 5%), hyponatremia (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (&ge;5%), anorexia (&ge;5%), cachexia (1% to 5%), constipation (1% to 5%), dyspepsia (1% to 5%), dysphagia (1% to 5%), flatulence (1% to 5%), melena (1% to 5%), pancreatitis (1% to 5%), rectal hemorrhage (1% to 5%), taste perversion (1% to 5%), ulcerative stomatitis (1% to 5%), weight loss (1% to 5%), xerostomia (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (1% to 5%), nocturia (1% to 5%), urinary retention (1% to 5%), urinary tract infection (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bone marrow suppression (10%), leukopenia (&ge;5%), lymphadenopathy (1% to 5%), thrombocytopenia (1% to 5%), thrombosis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (1% to 5%), ALT increased (1% to 5%), AST increased (1% to 5%), hepatic function abnormal (1% to 5%), LDH increased (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Abscess (1% to 5%), injection site pain/inflammation (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (&ge;5%), involuntary muscle contractions (&ge;5%), rigors (&ge;5%), neuropathy (peripheral; &ge;5%), weakness (&ge;5%), arthralgia (1% to 5%), back pain (1% to 5%), leg cramps (1% to 5%), myalgia (1% to 5%), tremor (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision abnormalities (&ge;5%), conjunctivitis (1% to 5%), eye pain (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Acute renal failure (1% to 5%), albuminuria (1% to 5%), BUN increased (1% to 5%), polyuria (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (&ge;5%), dyspnea (&ge;5%), bronchospasm (1% to 5%), hemoptysis (1% to 5%), pharyngitis (1% to 5%), pneumonia (1% to 5%), pneumothorax (1% to 5%), pulmonary infiltrates (1% to 5%), respiratory failure (1% to 5%), rhinitis (1% to 5%), sinusitis (1% to 5%), stridor (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (&ge;5%), sepsis (&ge;5%), flu-like syndrome (1% to 5%), infection (includes bacterial and fungal; 1% to 5%), malignancies (lymphoma/sarcoma 1% to 5%), thirst (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Cardiac arrest, coma, diabetes insipidus (usually nephrogenic), erythema multiforme, hematuria, hypoproteinemia, myositis, neutropenia, pancytopenia, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, renal calculus, rhabdomyolysis, Stevens-Johnson syndrome, syndrome of inappropriate antidiuretic hormone (SIADH), toxic epidermal necrolysis, ventricular arrhythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to foscarnet or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dental effects: Foscarnet is deposited in teeth and bone of young, growing animals; it has adversely affected tooth enamel development in rats.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Imbalance of serum electrolytes or minerals occurs in at least 15% of patients (hypocalcemia, low ionized calcium, hyper/hypophosphatemia, hypomagnesemia, or hypokalemia); reducing infusion rate may decrease/prevent symptoms. Patients with low ionized calcium may experience perioral tingling, numbness, paresthesias, tetany, and seizures. Correct electrolytes before initiating therapy; use caution in patients who have any underlying electrolyte imbalances, those with neurologic or cardiac abnormalities, and those receiving medications that are influenced by calcium levels. Use caution when administering other medications that cause electrolyte imbalances. Patients who experience signs or symptoms of an electrolyte imbalance should be assessed immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: May cause anemia and granulocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Renal impairment occurs to some degree in the majority of patients treated with foscarnet;",
"     </b>",
"     renal impairment may occur at any time (though typically during second week of induction therapy) and is usually reversible within 1 week following dose adjustment or discontinuation of therapy, however, several patients have died with renal failure within 4 weeks of stopping foscarnet; therefore, renal function should be closely monitored during both induction and maintenance therapy. To reduce the risk of nephrotoxicity and the potential to administer a relative overdose, always calculate the Cl",
"     <sub>",
"      cr",
"     </sub>",
"     even if serum creatinine is within the normal range. Dosage adjustments are recommended for renal dysfunction; safety and efficacy in patients with a baseline S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;2.8 mg/dL or Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute are limited. Use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;0.4 mL/kg/minute is not recommended. Adequate hydration may reduce the risk of nephrotoxicity; the manufacturer makes specific recommendations regarding this (see Administration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures:",
"     <b>",
"      [U.S. Boxed Warning]: Seizures related to plasma electrolyte/mineral imbalance may occur;",
"     </b>",
"     incidence has been reported in up to 10% of HIV patients. Risk factors for seizures include impaired baseline renal function, low total serum calcium, and underlying CNS condition. Some patients who have experienced seizures have been able to continue or resume foscarnet treatment after their mineral or electrolyte abnormality has been corrected, their underlying disease state treated, or their dose decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vascular irritant: Administer only into vein with adequate blood flow to prevent tissue irritation/ulceration. Genital vascular tissue damage has been reported; adequate hydration recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [U.S. Boxed Warning]: Indicated only for immunocompromised patients with CMV retinitis and mucocutaneous acyclovir-resistant HSV infection.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3051197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Associated with an increase in skeletal anomalies in animal studies at approximately the equivalent of 13% to 33% of the maximal daily human dose. There are no adequate and well controlled studies in pregnant women. A single case report of use during the third trimester with normal infant outcome was observed. Monitoring of amniotic fluid volumes by ultrasound is recommended weekly after 20 weeks of gestation to detect oligohydramnios.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F174157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The CDC recommends",
"     <b>",
"      not",
"     </b>",
"     to breast-feed if diagnosed with HIV to avoid postnatal transmission of the virus.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Foscarnet Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     24 mg/mL (250 mL): $91.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Foscavir Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     24 mg/mL (250 mL): $262.12",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3051199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     24-hour creatinine clearance at baseline and periodically thereafter. During induction therapy: Obtain complete blood counts, and electrolytes (including serum creatinine, calcium, magnesium, potassium, and phosphorus) twice weekly and then one weekly during maintenance therapy. More frequent monitoring may be required in some patients. Check hydration status before and after infusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Carnet (CL);",
"     </li>",
"     <li>",
"      Foscarnet Elea (AR);",
"     </li>",
"     <li>",
"      Foscarnet Filaxis (AR);",
"     </li>",
"     <li>",
"      Foscarnet Richmond (AR);",
"     </li>",
"     <li>",
"      Foscavir (AR, AT, AU, BE, BR, CH, CZ, DE, ES, FI, FR, GB, GR, HN, HU, IL, IT, JP, LU, NL, NO, NZ, PT, SE, SG);",
"     </li>",
"     <li>",
"      Fu Shi Ling (CL);",
"     </li>",
"     <li>",
"      Terap (AR);",
"     </li>",
"     <li>",
"      Triapten (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyrophosphate analogue which acts as a noncompetitive inhibitor of many viral RNA and DNA polymerases as well as HIV reverse transcriptase. Similar to ganciclovir, foscarnet is a virostatic agent. Foscarnet does not require activation by thymidine kinase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~0.5 L/kg; up to 28% of cumulative I.V. dose may be deposited in bone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 14% to 17%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Biotransformation does not occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Elimination: ~3-4 hours; terminal: ~88 hours (due to bone deposition)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&le;28% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aweeka FT, Jacobson MA, Martin-Munley S, et al, &ldquo;Effect of Renal Disease and Hemodialysis on Foscarnet Pharmacokinetics and Dosing Recommendations,&rdquo;",
"      <i>",
"       J Acquir Immune Def Syndr Hum Retrovirol",
"      </i>",
"      , 1999, 20(4):350-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/10096579/pubmed\" id=\"10096579\" target=\"_blank\">",
"        10096579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benson CA, Kaplan JE, Masur H, et al, &ldquo;Treating Opportunistic Infections Among HIV-Exposed and Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health and the HIV Medicine Association/IDSA,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      2004, 53(RR-15):1-112.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/15841069/pubmed\" id=\"15841069\" target=\"_blank\">",
"        15841069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Butler KM, DeSmet MD, Husson RN, et al, &ldquo;Treatment of Aggressive Cytomegalovirus Retinitis With Ganciclovir in Combination With Foscarnet in a Child Infected With Human Immunodeficiency Virus,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 120(3):483-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/1311378/pubmed\" id=\"1311378\" target=\"_blank\">",
"        1311378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Calligaro KD, Stern J, and DeLaurentis DA, &ldquo;Foscarnet: A Possible Cause of Ulnar Artery Thrombosis in a Patient With AIDS,&rdquo;",
"      <i>",
"       J Vasc Surg",
"      </i>",
"      , 1994, 20(6):1007-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/7990178/pubmed\" id=\"7990178\" target=\"_blank\">",
"        7990178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chilukuri S and Rosen T, \"Management of Acycovir-Resistant Herpes Simplex Virus,\"",
"      <i>",
"       Dermatol Clin",
"      </i>",
"      , 2003, 21(2):311-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/12757254/pubmed\" id=\"12757254\" target=\"_blank\">",
"        12757254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chrisp P and Clissold SP, &ldquo;Foscarnet. A Review of Its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Use in Immunocompromised Patients With Cytomegalovirus Retinitis,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1991, 41(1):104-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/1706982/pubmed\" id=\"1706982\" target=\"_blank\">",
"        1706982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deray G, Martinez F, Katlama C, et al, &ldquo;Foscarnet Nephrotoxicity: Mechanism, Incidence and Prevention,&rdquo;",
"      <i>",
"       Am J Nephrol",
"      </i>",
"      , 1989, 9:316-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/2554731/pubmed\" id=\"2554731\" target=\"_blank\">",
"        2554731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Non-HIV Viral Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1994, 36(919):27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/8127252/pubmed\" id=\"8127252\" target=\"_blank\">",
"        8127252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson MA, &ldquo;Review of the Toxicities of Foscarnet,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 1992, 5(Suppl 1):11-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jayaweera DT, &ldquo;Minimizing the Dosage-Limiting Toxicities of Foscarnet Induction Therapy,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1997, 16(4):258-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/9113493/pubmed\" id=\"9113493\" target=\"_blank\">",
"        9113493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating MR, &ldquo;Antiviral Agents,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1992, 67(2):160-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/1347578/pubmed\" id=\"1347578\" target=\"_blank\">",
"        1347578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mofenson LM, Oleske J, Serchuck L, et al, &ldquo;Treating Opportunistic Infections Among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 40 (Suppl 1):1-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/15655768 /pubmed\" id=\"15655768 \" target=\"_blank\">",
"        15655768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morales JM, Munoz MA, Fernandez Zatarain G, et al, &ldquo;Reversible Acute Renal Failure Caused by the Combined Use of Foscarnet and Cyclosporin in Organ Transplanted Patients,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 1995, 10(6):882-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/7566623/pubmed\" id=\"7566623\" target=\"_blank\">",
"        7566623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prevention and Treatment of Cancer-Related Infections,&rdquo; Version 1.2008. Available at  file://www.nccn.org/professionals/physician_gls/PDF/infections.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polis MA, &ldquo;Foscarnet and Ganciclovir in the Treatment of Cytomegalovirus Retinitis,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 1992, 5(Suppl 1):3-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whitley RJ, Jacobson MA, Friedberg DN, et al, &ldquo;Guidelines for the Treatment of Cytomegalovirus Diseases in Patients With AIDS in the Era of Potent Antiretroviral Therapy: Recommendations of an International Panel. International AIDS Society-USA,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(9):957-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29575/abstract-text/9588429/pubmed\" id=\"9588429\" target=\"_blank\">",
"        9588429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8476 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29575=[""].join("\n");
var outline_f28_56_29575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708811\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14934198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174208\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174170\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174190\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174171\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174172\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896285\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174148\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174134\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174151\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174214\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174150\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174204\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174206\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174154\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174138\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299364\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174143\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174145\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3051197\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174177\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174157\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323160\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3051199\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038643\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174137\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174153\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8476\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8476|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/11/37044?source=related_link\">",
"      Foscarnet: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/4/24646?source=related_link\">",
"      Foscarnet: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_56_29576="Interferon alfa-2b: Drug information";
var content_f28_56_29576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Interferon alfa-2b: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/61/14294?source=see_link\">",
"    see \"Interferon alfa-2b: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/47/40695?source=see_link\">",
"    see \"Interferon alfa-2b: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intron&reg; A",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Intron&reg; A",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted. Consider premedication with acetaminophen prior to administration to reduce the incidence of some adverse reactions. Not all dosage forms and strengths are appropriate for all indications; refer to product labeling for details.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hairy cell leukemia:",
"     </b>",
"     I.M., SubQ: 2 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     3 times weekly for up to 6 months (may continue treatment with sustained treatment response); discontinue for disease progression or failure to respond after 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lymphoma (follicular):",
"     </b>",
"     SubQ: 5 million units 3 times weekly for up to 18 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malignant melanoma:",
"     </b>",
"     Induction: 20 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     I.V. for 5 consecutive days per week for 4 weeks, followed by maintenance dosing of  10 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     SubQ 3 times weekly for 48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      AIDS-related Kaposi's sarcoma:",
"     </b>",
"     I.M., SubQ: 30 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     3 times weekly; continue until disease progression or until maximal response has been achieved after 16 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis B:",
"     </b>",
"     I.M., SubQ: 5 million units/ daily or 10 million units 3 times weekly for 16 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C:",
"     </b>",
"     I.M., SubQ: 3 million units 3 times weekly. In patients with normalization of ALT at 16 weeks, continue treatment (if tolerated) for 18-24 months; consider discontinuation if normalization does not occur at 16 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     May be used in combination therapy with ribavirin in previously untreated patients or in patients who relapse following alpha interferon therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Condyloma acuminata:",
"     </b>",
"     Intralesionally: 1 million units/lesion (maximum: 5 lesions per treatment) 3 times weekly (on alternate days) for 3 weeks. May administer a second course at 12-16 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F183218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/47/40695?source=see_link\">",
"      see \"Interferon alfa-2b: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The following dosing may also be used in",
"     <b>",
"      infants",
"     </b>",
"     in the setting of HIV-exposure/-infection (CDC, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis B (including HIV coinfection):",
"     </b>",
"     SubQ: Children 1-17 years: 3 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     3 times weekly for 1 week, followed by 6 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     3 times weekly (maximum: 10 million units per dose); total duration of therapy 16-24 weeks (treat for 24 weeks in HIV-exposure/-infection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C with HIV coinfection:",
"     </b>",
"     I.M., SubQ: Children 1-17 years: 3-5 million units/m",
"     <sup>",
"      2",
"     </sup>",
"     3 times weekly (maximum: 3 million units per dose) with ribavirin for 48 weeks, regardless of HCV genotype (CDC, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F183208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F249801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination therapy with ribavirin (hepatitis C) should not be used in patients with reduced renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F183228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic toxicity (also refer to indication specified adjustments below): ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt; 25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Hypersensitivity reaction (acute, serious), ophthalmic disorders (new or worsening), thyroid abnormality development (which cannot be normalized with medication), signs or symptoms of liver failure: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Liver function abnormality, pulmonary infiltrate development, evidence of pulmonary function impairment, or autoimmune disorder development, triglycerides &gt;1000 mg/dL: Monitor closely and discontinue if appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Neuropsychiatric disorders (during treatment):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Clinical depression or other psychiatric problem:",
"     </i>",
"     Monitor closely during and for 6 months after treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Severe depression or other psychiatric disorder:",
"     </i>",
"     Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Persistent or worsening psychiatric symptoms, suicidal ideation, aggression towards others:",
"     </i>",
"     Discontinue treatment and follow with appropriate psychiatric intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Manufacturer-recommended adjustments, listed according to indication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Lymphoma (follicular):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrophils &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     to &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Reduce dose by 50%; may re-escalate to starting dose when neutrophils return to &gt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe toxicity (neutrophils &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ): Temporarily withhold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AST &gt;5 times ULN or serum creatinine &gt;2 mg/dL: Permanently discontinue.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Hairy cell leukemia:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Do not administer intramuscularly (administer SubQ instead).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe toxicity: Reduce dose by 50% or temporarily withhold and resume with 50% dose reduction; permanently discontinue if persistent or recurrent severe toxicity is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Chronic hepatitis B",
"     </i>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , granulocytes &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or other laboratory abnormality or severe adverse reaction: Reduce dose by 50%; may re-escalate to starting dose upon resolution of hematologic toxicity. Discontinue for persistent intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     WBC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , granulocytes &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelet count &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Permanently discontinue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Chronic hepatitis C:",
"     </i>",
"     Severe toxicity: Reduce dose by 50% or temporarily withhold until subsides; permanently discontinue for persistent toxicities after dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      AIDS-related Kaposi sarcoma:",
"     </i>",
"     Severe toxicity: Reduce dose by 50% or temporarily withhold; may resume at reduced dose with toxicity resolution; permanently discontinue for persistent/recurrent toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Malignant melanoma (induction and maintenance):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe toxicity including neutrophils &gt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     to &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or ALT/AST &gt;5-10 times ULN: Temporarily withhold; resume with a 50% dose reduction when adverse reaction abates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrophils &lt;250/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ALT/AST &gt;10 times ULN, or severe/persistent adverse reactions: Permanently discontinue.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intron&reg; A: 10 million units, 18 million units, 50 million units [contains albumin (human)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intron&reg; A: 6 million units/mL (3 mL); 10 million units/mL (2.5 mL) [contains edetate disodium, polysorbate 80; vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intron&reg; A: 3 million units/0.2 mL (1.2 mL) [contains edetate disodium, polysorbate 80; delivers 6 doses of 0.2 mL each; 18 million units total per prefilled pen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intron&reg; A: 5 million units/0.2 mL (1.2 mL) [contains edetate disodium, polysorbate 80; delivers 6 doses of 0.2 mL each; 30 million units total per prefilled pen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intron&reg; A: 10 million units/0.2 mL (1.2 mL) [contains edetate disodium, polysorbate 80; delivers 6 doses of 0.2 mL each; 60 million units total per prefilled pen]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111337.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm111337.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F183186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer dose in the evening (if possible) to enhance tolerability. Not all dosage forms are recommended for all administration routes; refer to manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Rotate injection sites. Some patients may be appropriate for self-administration with appropriate training.  Allow to reach room temperature prior to injection. In hairy cell leukemia treatment, if platelets are &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , do not administer intramuscularly (administer SubQ instead).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse over ~20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: Suggested for those who are at risk for bleeding or are thrombocytopenic. Rotate SubQ injection site. Patient should be well hydrated. Some patients may be appropriate for self-administration with appropriate training.  Allow to reach room temperature prior to injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intralesional: Inject at an angle nearly parallel to the plane of the skin, directing the needle to center of the base of the wart to infiltrate the lesion core and cause a small wheal. Only infiltrate the keratinized layer; avoid administration which is too deep or shallow. Allow to reach room temperature prior to injection.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F183235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in LR, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients &ge;1 year of age: Chronic hepatitis B",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients &ge;3 years of age: Chronic hepatitis C (in combination with ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients &ge;18 years of age: Condyloma acuminata, chronic hepatitis B, chronic hepatitis C, hairy cell leukemia, malignant melanoma (high-risk of recurrence), AIDS-related Kaposi's sarcoma, follicular non-Hodgkin lymphoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F183223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cutaneous ulcerations of Beh&ccedil;et's disease, neuroendocrine tumors (including carcinoid syndrome and islet cell tumor), cutaneous T-cell lymphoma, desmoid tumor, hepatitis D, chronic myelogenous leukemia (CML), non-Hodgkin lymphomas (other than follicular lymphoma, see approved use), multiple myeloma, renal cell carcinoma, West Nile virus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F183238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Interferon alfa-2b may be confused with interferon alfa-2a, interferon alfa-n3, pegylated interferon alfa-2b",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Intron&reg; A may be confused with PEG-Intron",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Interferon alfa-2b may be confused with interferon alpha multi-subtype which is available in international markets",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In a majority of patients, a flu-like syndrome (fever, chills, tachycardia, malaise, myalgia, headache), occurs within 1-2 hours of administration; may last up to 24 hours and may be dose limiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (&le;28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (8% to 96%), fever (34% to 94%; more common in children), headache (21% to 62%), chills (&le;54%), depression (3% to 40%; grades 3/4: 2%), somnolence (&le;33%), dizziness (&le;24%), irritability (&le;22%), pain (&le;18%), amnesia (&le;14%), concentration impaired (&le;14%), malaise (&le;14%), confusion (&le;12%), insomnia (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (&le;38%), rash (&le;25%), pruritus (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (1% to 69%), nausea, (17% to 66%), diarrhea (2% to 45%),  xerostomia (&le;28%), vomiting (children 27%; adults 7% to 10%), taste alteration (&le;24%), abdominal pain (1% to 23%), constipation (&le;14%), gingivitis (&le;14%), weight loss (&lt;1% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (&le;92%; grade 4: 1% to 4%), leukopenia (&le;68%), anemia (&le;32%), thrombocytopenia (&le;15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (&le;63%; grades 3/4: 14%), ALT increased (&le;15%), pain (upper right quadrant: up to 15%); alkaline phosphatase increased (&le;13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (&le;20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (28% to 75%), weakness (&le;63%), rigors (&le;42%), paresthesia (1% to 21%), skeletal pain (&le;21%), arthralgia (&le;19%), back pain (&le;19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (&le;34%), cough (&le;31%), pharyngitis (&le;31%), sinusitis (&le;21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous:  Flu-like syndrome (&le;79%), diaphoresis (1% to 21%), moniliasis (&le;17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (&le;10%), hypertension (&le;9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hypoesthesia (&le;10%), anxiety (&le;9%), vertigo (&le;8%), agitation (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dry skin (&le;10%), dermatitis (&le;8%), purpura (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Loose stools (&le;10%), dyspepsia (&le;8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Polyuria (&le;10%), serum creatinine increased (&le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (&le;10%), nasal congestion (&le;10%), epistaxis (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (&le;7%), herpes virus infections (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5% (Limited to important or life-threatening): Acute hypersensitivity reaction, aggression, albuminuria, alcohol intolerance, allergic reactions, anaphylaxis, angina, angioedema, aphasia, aplastic anemia (rarely), arrhythmia, ascites, asthma, ataxia, atrial fibrillation, bell's palsy, bilirubinemia, blurred vision, bradycardia, bronchiolitis obliterans, bronchoconstriction, bronchospasm, cardiac failure, cardiomegaly, cardiomyopathy, cellulitis, colitis, coma, conjunctivitis, coronary artery disorder, cotton wool spots, cyanosis, cystitis, dehydration, diabetes mellitus, dysphasia, dysuria, eczema, ejection fraction decreased, epidermal necrolysis, erythema, erythema multiforme, erythematous rash, esophagitis, extrapyramidal disorder, extrasystoles, gastrointestinal hemorrhage, granulocytopenia, hallucination, hearing loss/impairment, heart valve disorder, hematuria, hemolytic anemia, hemoptysis, hepatic encephalopathy, hepatic failure, hepatitis, hepatotoxicity, hot flashes, homicidal ideation, hyper-/hypothyroidism, hypercalcemia, hyperglycemia, hypertriglyceridemia, hypochromic anemia, hypopituitarism, hypotension, hypothermia, hypoventilation, impotence, incontinence, injection site necrosis, jaundice, lactate dehydrogenase increased, leukorrhea, liver function test abnormal, lupus erythematosus, lymphadenitis, lymphadenopathy, lymphocytosis, lymphopenia, maculopapular rash, macular edema, menorrhagia, MI, migraine, muscle atrophy, myositis,  nephrotic syndrome, nervousness, neuralgia, neuropathy, neurosis, nystagmus, optic neuritis, palpitation, pancreatitis, pancytopenia, papilledema, paranoia, peripheral ischemia, peripheral neuropathy, photophobia, photosensitivity, pleural effusion, pneumonia, pneumonitis (interstitial), pneumothorax, proteinuria, psoriasis exacerbation, psychosis, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension, pulmonary infiltrates, pure red cell aplasia, Raynaud's disease, renal failure, renal insufficiency, respiratory insufficiency, retinal artery thrombosis, retinal detachment (serous), retinal vein thrombosis, rhabdomyolysis, sarcoidosis exacerbation, sebaceous cyst, seizure, sepsis, sexual dysfunction, Stevens-Johnson syndrome, stomatitis, stroke, suicidal attempt/ideation, syncope, systemic lupus erythematosus, tachycardia, tendonitis, thrombocytopenia purpura (idiopathic and thrombotic), thrombosis, toxic epidermal necrolysis, upper respiratory tract infection, urticaria, uterine bleeding, vasculitis, Vogt-Koyanagi-Harada syndrome, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to interferon alfa or any component of the formulation; decompensated liver disease; autoimmune hepatitis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Combination therapy with interferon alfa-2b and ribavirin is also contraindicated in pregnancy, males with pregnant partners; hemoglobinopathies (eg, thalassemia major, sickle-cell anemia); renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F183172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias, and very rarely, aplastic anemia. Discontinue treatment for severe neutropenia (ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or thrombocytopenia (platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ). Hemolytic anemia (hemoglobin &lt;10 g/dL) was observed in up to 10% of treated patients in clinical trials when combined with ribavirin; anemia occurred within 1-2 weeks of initiation of therapy. Use caution in patients with pre-existing myelosuppression and in patients with concomitant medications which cause myelosuppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Hemorrhagic and ischemic cerebrovascular events have been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flu-like symptoms: Commonly associated with fever and flu-like symptoms; rule out other causes/infections with persistent fever. Use with caution in patients with debilitating conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic effects: May cause hepatotoxicity; monitor closely if abnormal liver function tests develop. A transient increase in ALT (&ge;2 times baseline) may occur in patients treated with interferon alfa-2b for chronic hepatitis B. Therapy generally may continue, however, functional indicators (eg, albumin, prothrombin time, bilirubin) should be monitored frequently. Worsening and potentially fatal liver disease, including jaundice, hepatic encephalopathy, and hepatic failure have been reported in patients receiving interferon alfa for chronic hepatitis B and C with decompensated liver disease, autoimmune hepatitis, history of autoimmune disease, and immunosuppressed transplant recipients; avoid interferon treatment (if appropriate) in these patients. Discontinue treatment in any patient developing signs or symptoms of liver failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Acute hypersensitivity reactions have been reported (rarely) with alfa interferons.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertriglyceridemia: Has been reported (discontinue if persistent and severe, particularly if combined with symptoms of pancreatitis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate severe neuropsychiatric adverse events; monitor closely with clinical evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.",
"     </b>",
"     Psychiatric events may include depression, psychosis, mania, suicidal behavior/ideation, homicidal ideation, and may occur in patients with or without previous psychiatric symptoms. Careful neuropsychiatric monitoring is recommended during and for 6 months after treatment in patients who develop psychiatric disorders (including clinical depression). New or exacerbated neuropsychiatric or substance abuse disorders are best managed with early intervention.  Use with caution in patients with a history of psychiatric disorders. Drug screening and periodic health evaluation (including monitoring of psychiatric symptoms) is recommended if initiating treatment in patients with coexisting psychiatric condition or substance abuse disorders. Suicidal ideation or attempts may occur more frequently in pediatric patients when compared to adults. Higher doses in elderly patients, or diseases other than hairy cell leukemia, may result in increased CNS toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Decreased or loss of vision, macular edema, optic neuritis, retinal hemorrhages, cotton wool spots, papilledema, retinal detachment (serous), and retinal artery or vein thrombosis have occurred (or been aggravated) in patients receiving alfa interferons. Use caution in patients with pre-existing eye disorders; monitor closely; a complete eye exam should be done promptly in patients who develop ocular symptoms; discontinue with new or worsening ophthalmic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary effects: Dyspnea, pulmonary infiltrates, pulmonary hypertension, interstitial pneumonitis, pneumonia, bronchiolitis obliterans, and sarcoidosis may be induced or aggravated by treatment, sometimes resulting in respiratory failure or fatality. Has been reported more in patients being treated for chronic hepatitis C, although has also occurred with use for oncology indications. Patients with fever, cough, dyspnea or other respiratory symptoms should be evaluated with a chest x-ray; monitor closely and consider discontinuing treatment with evidence of impaired pulmonary function. Use with caution in patients with a history of pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; AIDS-related Kaposi's sarcoma: Do not treat patients with visceral AIDS-related Kaposi's sarcoma associated with rapidly-progressing or life-threatening disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disease:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate fatal or life-threatening autoimmune disorders; monitor closely with clinical and lab evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.",
"     </b>",
"     Autoimmune disorders (thrombocytopenia, vasculitis, Raynaud&rsquo;s disease, rheumatoid arthritis, lupus erythematosus and rhabdomyolysis) have been associated with alfa interferons. Worsening of psoriasis and sarcoidosis (and the development of new sarcoidosis) have been reported; use caution in patients with these conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution and monitor closely in patients with cardiovascular disease (ischemic or thromboembolic), arrhythmias, hypertension, and in patients with a history of MI or prior therapy with cardiotoxic drugs. Patients with pre-existing cardiac disease and/or advanced cancer should have baseline and periodic ECGs. May cause hypotension (during administration or delayed), arrhythmia, tachycardia, cardiomyopathy (~2% in AIDS-related Kaposi&rsquo;s Sarcoma patients) and/or MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic hepatitis: Patients being treated for chronic hepatitis B or C with a history of autoimmune disease or who are immunosuppressed transplant recipients should not receive interferon alfa-2b.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coagulation disorders: Use with caution and monitor closely in patients with coagulation disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Has been reported; discontinue if diabetes cannot be effectively managed with medication. Use with caution in patients with a history of diabetes mellitus, particularly if prone to DKA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate fatal or life-threatening infectious disorders; monitor closely with clinical and lab evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate fatal or life-threatening ischemic disorders; monitor closely with clinical and lab evaluations (periodic); discontinue treatment for severe persistent or worsening symptoms; some cases may resolve with discontinuation.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disorders: Use with caution in patients with pre-existing thyroid disease; thyroid disorders (hyper- or hypothyroidism) have been reported. Some have been irreversible upon discontinuation of treatment. TSH levels should be within normal limits prior to initiating interferon. Discontinue interferon use in patients with thyroid disease who cannot maintain normal ranges with thyroid medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Combination therapy with ribavirin: Combination therapy with ribavirin is associated with birth defects and/or fetal mortality and hemolytic anemia. Do not use combination therapy with ribavirin in patients with renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Some formulations contain albumin, which may carry a remote risk of viral transmission, including a theoretical risk of Creutzfeldt-Jakob disease transmission.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product variability:",
"     <b>",
"      Due to differences in dosage, patients should not change brands of interferons without the concurrence of their healthcare provider.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F183220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Interferons (Alfa) may increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telbivudine: Interferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C / X in combination with ribavirin (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated abortifacient effects. Disruption of the normal menstrual cycle was also observed in animal studies; therefore, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid.",
"     <i>",
"      In vitro",
"     </i>",
"     administration studies have reported that when administered to the mother, it does not cross the placenta. Case reports of use in pregnant women are limited. The Perinatal HIV Guidelines Working Group does not recommend that interferon-alfa be used during pregnancy. Interferon alfa-2b monotherapy should only be used in pregnancy when the potential benefit to the mother justifies the possible risk to the fetus. Combination therapy with ribavirin is contraindicated in pregnancy (refer to Ribavirin monograph); two forms of contraception should be used during combination therapy and patients should have monthly pregnancy tests. A pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F183192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast milk samples obtained from a lactating mother prior to and after administration of interferon alfa-2b showed that interferon alfa is present in breast milk and administration of the medication did not significantly affect endogenous levels. Breast-feeding is not linked to the spread of hepatitis C virus; however, if nipples are cracked or bleeding, breast-feeding is not recommended. Mothers coinfected with HIV are discouraged from breast-feeding to decrease potential transmission of HIV.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Intron-A Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6000000 units/mL (3.8 mL): $517.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000000 units/mL (3.2 mL): $718.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Intron-A Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000000 unit (1): $223.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18000000 unit (1): $402.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50000000 unit (1): $1117.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F183181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline and periodic during treatment), liver function tests (baseline and periodic), electrolytes (baseline and periodic), serum creatinine (baseline), albumin, prothrombin time, triglycerides, thyroid-stimulating hormone (TSH) baseline and periodically during treatment (in patients with pre-existing thyroid disorders, repeat TSH at 3 months and 6 months); chest x-ray (baseline), weight; ophthalmic exam (baseline and periodic, or with new ocular symptoms); ECG (baseline and during treatment; in patients with pre-existing cardiac abnormalities or in advanced stages of cancer); neuropsychiatric changes during and for 6 months after therapy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chronic hepatitis B: CBC with differential and platelets and liver function tests: Baseline, weeks 1, 2, 4, 8, 12, and 16, at the end of treatment, and then 3 and 6 months post treatment",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     Chronic hepatitis C:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     CBC with differential and platelets: Baseline, weeks 1 and 2, then monthly",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Liver function: Every 3 months",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     TSH: Baseline and periodically during treatment; in patients with pre-existing thyroid disorders also repeat at 3 months and 6 months",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Malignant melanoma: CBC with differential and platelets and liver function tests: Weekly during induction phase, then monthly during maintenance",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Oncology patients: Thyroid function monitoring (Hamnvik, 2011): TSH and anti-TPO antibodies at baseline; if TPO antibody positive, monitor TSH every 2 months; if TPO antibody negative, monitor TSH every 6 months",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bioferon (PY, TH, UY);",
"     </li>",
"     <li>",
"      Enduferon (PH);",
"     </li>",
"     <li>",
"      FNI 2B (MX);",
"     </li>",
"     <li>",
"      Heberon Alfa R (CO);",
"     </li>",
"     <li>",
"      Intron A (AR, AT, AU, BE, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IT, JP, KE, MT, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, RU, SE, SK, SV, TR, TW, VE);",
"     </li>",
"     <li>",
"      Intron-A (GR, ID, MY, SG);",
"     </li>",
"     <li>",
"      Introna (AT, DK, FI, FR, NO, SE);",
"     </li>",
"     <li>",
"      Kaifu (CL);",
"     </li>",
"     <li>",
"      Peg-Intron (HK, KP);",
"     </li>",
"     <li>",
"      Realdiron (BG);",
"     </li>",
"     <li>",
"      Realfa (IN);",
"     </li>",
"     <li>",
"      Viraferon (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F183171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to a specific receptor on the cell wall to initiate intracellular activity; multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F183188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 31 L; but has been noted to be much greater (370-720 L) in leukemia patients receiving continuous infusion IFN; IFN does not penetrate the CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily renal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M.: 83%; SubQ: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: ~2 hours; I.M., SubQ: ~2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M., SubQ: ~3-12 hours; I.V.: By the end of a 30-minute infusion",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):941-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/17906043/pubmed\" id=\"17906043\" target=\"_blank\">",
"        17906043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Atkins MB, Hsu J, Lee S, et al, &ldquo;Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(35):5748-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/19001327/pubmed\" id=\"19001327\" target=\"_blank\">",
"        19001327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balkwill FR and Smyth JF, &ldquo;Interferons in Cancer Therapy: A Reappraisal,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1987, 2(8554):317-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gresser I, &ldquo;Biologic Effects of Interferons,&rdquo;",
"      <i>",
"       J Invest Dermatol",
"      </i>",
"      , 1990, 95(6 Suppl):66-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Houglum JE, &ldquo;Interferon: Mechanisms of Action and Clinical Value,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1983, 2(1):20-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/6192965/pubmed\" id=\"6192965\" target=\"_blank\">",
"        6192965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&ouml;tter I, G&uuml;naydin I, Zierhut M, et al, &ldquo;The Use of Interferon Alpha in Beh&ccedil;et Disease: Review of the Literature,\"",
"      <i>",
"       Semin Arthritis Rheum",
"      </i>",
"      , 2004, 33(5):320-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/15079763/pubmed\" id=\"15079763\" target=\"_blank\">",
"        15079763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lebon P, Girard S, Thepot F, et al, &ldquo;The Presence of Alpha-Interferon in Human Amniotic Fluid,&rdquo;",
"      <i>",
"       J Gen Virol",
"      </i>",
"      , 1982, 59(Pt 2):393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/6176680/pubmed\" id=\"6176680\" target=\"_blank\">",
"        6176680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Legha SS, &ldquo;The Role of Interferon Alfa in the Treatment of Metastatic Melanoma,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1997, 24(1 Suppl 4):24-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Musselman DL, Lawson DH, Gumnick JF, et al, &ldquo;Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(13):961-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/11274622/pubmed\" id=\"11274622\" target=\"_blank\">",
"        11274622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pectasides D, Dafni U, Bafaloukos D, et al, &ldquo;Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      ,  2009, 27(6):939-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/19139440/pubmed\" id=\"19139440\" target=\"_blank\">",
"        19139440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tilg H, &ldquo;New Insights Into the Mechanisms of Interferon Alfa: An Immunoregulatory and Anti-Inflammatory Cytokine,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1997, 112(3):1017-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/9041265/pubmed\" id=\"9041265\" target=\"_blank\">",
"        9041265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vial T and Descotes J, &ldquo;Clinical Toxicity of the Interferons,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1994, 10(2):115-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/7516663/pubmed\" id=\"7516663\" target=\"_blank\">",
"        7516663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waysbort A, Giroux M, Mansat V, et al, &ldquo;Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1993, 37(6):1232-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/8328774/pubmed\" id=\"8328774\" target=\"_blank\">",
"        8328774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wills RJ, &ldquo;Clinical Pharmacokinetics of Interferons,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(5):390-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/56/29576/abstract-text/1702693/pubmed\" id=\"1702693\" target=\"_blank\">",
"        1702693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8563 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-118.195.65.248-57510F31CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29576=[""].join("\n");
var outline_f28_56_29576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708923\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183204\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183205\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183227\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183207\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183218\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183208\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F249801\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897897\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183228\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183183\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183168\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874825\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183186\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183235\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183184\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183223\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183238\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183225\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183189\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183172\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183220\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183177\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183179\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183191\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183213\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183192\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524635\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183181\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183193\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183171\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183188\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8563|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/61/14294?source=related_link\">",
"      Interferon alfa-2b: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/47/40695?source=related_link\">",
"      Interferon alfa-2b: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_56_29577="Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy";
var content_f28_56_29577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29577/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29577/contributors\">",
"     Rachel A Nardin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29577/contributors\">",
"     Roy Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29577/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29577/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29577/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29577/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/56/29577/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of distinctive neuropathic syndromes, which can be classified according to the timing of their appearance during HIV infection, their etiology, and whether they are primarily axonal or demyelinating. The most common of these is peripheral neuropathy, also referred to as distal symmetric peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will cover the pathogenesis, clinical manifestations, diagnosis, and treatment of distal symmetric peripheral neuropathy. The clinical manifestations of other HIV-associated neuropathies (eg, acquired inflammatory demyelinating polyradiculoneuropathy, cauda equina syndrome, diffuse infiltrative lymphocytosis syndrome (DILS), autonomic neuropathy, mononeuropathies, herpes zoster radiculitis, sensory ganglioneuritis) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link\">",
"     \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of distal symmetrical polyneuropathy (DSPN) in different series has varied from 9 to 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. This variability reflects differences in the degree of immunosuppression (higher prevalence with more advanced disease), in the definition of the neuropathy (symptomatic or asymptomatic), and in exposure to neurotoxic antiretrovirals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ]. Because of known neurotoxicities,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    are no longer recommended for the treatment of HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link&amp;anchor=H29#H29\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Nucleoside analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the era prior to potent antiretroviral therapy (ART), DSPN usually occurred in the setting of advanced immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/3,9,11-13\">",
"     3,9,11-13",
"    </a>",
"    ]. In one report, for example, the mean CD4 count was",
"    <span class=\"nowrap\">",
"     113/microL",
"    </span>",
"    (range 26 to 275",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to immunosuppression, the level of HIV viremia was also correlated with the development of DSPN and the severity of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/5,14,15\">",
"     5,14,15",
"    </a>",
"    ]. In the Multicenter AIDS Cohort Study, the risk of DSPN was increased 2.3-fold in patients with an HIV RNA level &gt;10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the era of potent ART, immunosuppression or high levels of viremia have not been associated with the development of DSPN in the vast majority of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/5,6,8,16-18\">",
"     5,6,8,16-18",
"    </a>",
"    ]. Co-infection with hepatitis C also does not appear to be associated with DSPN [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/6,19\">",
"     6,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors associated with DSPN include aging, host factors such as diabetes, nutritional deficiencies, mitochondrial polymorphisms, and the use of older nucleoside reverse transcriptase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/5,6,20-22\">",
"     5,6,20-22",
"    </a>",
"    ]. In a large prospective study, 2141 HIV-infected patients were followed longitudinally for seven years with annual screening for symptoms and signs of peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/23\">",
"     23",
"    </a>",
"    ]. The risk of peripheral neuropathy was associated with aging and nucleoside analog use while sensory loss was associated with older age, nucleoside analog use and diabetes.",
"   </p>",
"   <p>",
"    The role of certain antiretroviral medications is discussed below. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Role of drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect of antiretroviral therapy on natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies, the incidence of HIV-associated DSPN appears to have decreased in the era of potent ART compared with earlier cohorts, suggesting that effective suppression of HIV itself may have a beneficial effect on peripheral nerve function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/5,7,15,16,24\">",
"     5,7,15,16,24",
"    </a>",
"    ]. As an example, in a large cohort of 2515 HIV-infected patients, certain drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , and certain protease inhibitors) were associated with the development of DSPN in the first year of use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/5\">",
"     5",
"    </a>",
"    ]. However, patients who did not develop DSPN in the first year of ART had a decreased risk of developing this complication with continued drug exposure. In another cohort of 2165 patients followed for more than 3 years, incidence rates of peripheral neuropathy also declined with the initiation of ART [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/25\">",
"     25",
"    </a>",
"    ]. These data suggest that immune restoration, or viral suppression of HIV, lead to a decreased risk of DSPN [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of DSPN is incompletely understood and may be multifactorial. DSPN is termed a \"dying-back\" neuropathy to reflect the pattern of distal fiber loss [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/26\">",
"     26",
"    </a>",
"    ]. It involves myelinated and unmyelinated axons of all sizes; this pattern of axon loss is indistinguishable from that seen with other toxic neuropathies.",
"   </p>",
"   <p>",
"    There is a paucity of virus and associated inflammation in the peripheral nerves of patients with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/26\">",
"     26",
"    </a>",
"    ]. Although there are some case reports of HIV being cultured from peripheral nerve, it is widely accepted that almost all recovered virus is from the resident macrophages and monocytes that migrate to areas of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. HIV itself may lead to local axonal injury through two separate mechanisms, both of which appear to be triggered by envelope protein gp120 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/31\">",
"     31",
"    </a>",
"    ]. One indirect route is via neuronal apoptosis; the other is through direct, local toxicity mediated through activation of mitochondrial caspases. Likely more important, however, is the role that viral antigens play in provoking immune activation and inducing a microenvironment that is toxic to the peripheral nerve, as demonstrated by the following in vitro data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunohistochemical studies show macrophage and T cell infiltration of peripheral nerves and dorsal root ganglia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/30,32\">",
"       30,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Activated cytokines are found in the dorsal root ganglia of HIV-infected patients with distal symmetrical polyneuropathy raising the possibility of a multifocal, immunologically mediated inflammatory disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV gp120 activates Schwann cells via its chemokine receptor (CXCR4), leading both to neuronal apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/31\">",
"       31",
"      </a>",
"      ] and to production and release of tumor necrosis factor and other proinflammatory cytokines, which are directly toxic to neurons [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV infection is associated with a reduction in mitochondrial DNA content and changes in morphology [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not only does HIV infection result in nerve damage, but recent data suggests that reinnervation is impaired in patients with HIV infection, limiting the ability of the peripheral nervous system to heal itself [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cases of distal symmetrical polyneuropathy are iatrogenic, due to intrinsic neuronal toxicities of certain antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. The neuropathy is indistinguishable electrophysiologically from HIV-associated DSPN, although the hands may be affected more often in drug-induced cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/10,37-40\">",
"     10,37-40",
"    </a>",
"    ]. The incidence of neuropathy is dose-dependent and increases with the duration of drug exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/41\">",
"     41",
"    </a>",
"    ]. The onset is typically seven to nine weeks after beginning therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Dideoxynucleosides",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of drug-related neuropathy has been shown to correlate directly with the degree of mitochondrial toxicity of particular nucleoside reverse transcriptase inhibitors, although a direct link between toxicity and oxidant stress has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/24,43-46\">",
"     24,43-46",
"    </a>",
"    ]. Commonly implicated agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (d4T) and to a lesser extent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (ddI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/6,43\">",
"     6,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neurotoxicity of the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    was illustrated in a multicenter, randomized, partially double-blind trial of 620 antiretroviral-naive patients who were assigned to sequential three-drug regimens with different nucleoside analogues [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/47\">",
"     47",
"    </a>",
"    ]. At a median of 2.3 years, symptomatic peripheral neuropathy was significantly more likely in patients treated with regimens containing didanosine and stavudine compared to those containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (27 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic determinants may also play a role in risk in drug-induced DSPN:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 509 HIV-infected patients, mitochondrial haplotype T was more common in those patients who developed DSPN [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/48\">",
"       48",
"      </a>",
"      ]. Among 137 Caucasian subjects randomized to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      , 21 percent of those who developed peripheral neuropathy belonged to mitochondrial haplogroup T compared to five percent of control subjects (odds ratio, 5.4).",
"     </li>",
"     <li>",
"      In a case-control study, hemochromatosis gene mutations were associated with a decreased risk of developing DSPN during dideoxynucleoside therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/49\">",
"       49",
"      </a>",
"      ]. This protective effect may be related to the requirement of iron for mitochondrial function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential neurotoxicity of antiretroviral drugs does not preclude their use, since the beneficial effects on viral load suppression and immune function recovery appears to outweigh their potential neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/4,5,16,17\">",
"     4,5,16,17",
"    </a>",
"    ]. This apparent effect was illustrated in a report of 272 HIV-infected patients with CD4 counts less than 300",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    who were followed for 30 months; the use of dideoxynucleosides did not increase the risk of peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly, dideoxynucleoside antiretroviral therapy was not a predictor of progression of distal sensory polyneuropathy in a cohort of 101 individuals with advanced HIV infection who were followed for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some early data had suggested a potential role of protease inhibitors (PIs) in the pathogenesis of DSPN. One small study, which enrolled 101 patients with DSPN from 1998 to 2004, suggested an association with early generation protease inhibitors (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ) compared to later generation PIs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/50\">",
"     50",
"    </a>",
"    ]. The implications of these findings were unclear since most of these patients were also taking agents with known neurotoxicity, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    These findings prompted a much larger prospective, observational, multicenter study of current and past exposure to PIs as a risk factor for DSPN in 1159 HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/51\">",
"     51",
"    </a>",
"    ]. Although PI use was associated with an increased risk of DSPN in the univariate analysis, this association disappeared after adjusting for previously validated concomitant risk factors, such as dideoxynucleoside use.",
"   </p>",
"   <p>",
"    Furthermore, the clinical importance of these findings is less relevant now since none of these agents are used as first line agents for the treatment of HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other drugs that can lead to the onset of DSPN include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       Vincristine",
"      </a>",
"      , which may be used to treat Kaposi's sarcoma",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      , which may be used to treat or prevent Pneumocystis jirovecii (formerly carinii) pneumonia",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      , which may be used to treat aphthous ulcers",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       Isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      , which are used to treat tuberculosis",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       Nevirapine",
"      </a>",
"      , a non-nucleoside reverse transcriptase inhibitor, used to treat HIV infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Host genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human mitochondrial DNA sequences have diverged over time because of natural selection and human migration leading to distinct patterns of single nucleotide polymorphisms, called haplogroups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/52\">",
"     52",
"    </a>",
"    ]. Two studies in both non-Hispanic white [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/48\">",
"     48",
"    </a>",
"    ] and non-Hispanic black patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/53\">",
"     53",
"    </a>",
"    ] suggest that variations in these haplogroups may explain host susceptibility to mitochondrial drug injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DSPN usually manifests as bilateral tingling, and numbness in the toes. The neuropathy gradually spreads proximally in the lower extremities, with only rare involvement of the upper extremities. The spread of sensory symptoms usually occurs over weeks to months. Neuropathic pain is common and may be the presenting symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic examination shows sensory loss to all sensory modalities (vibration, pinprick, temperature) in a stocking distribution, while deep tendon reflexes are reduced or absent at the ankles and occasionally at the knees in more severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/4\">",
"     4",
"    </a>",
"    ]. Distal weakness in the lower extremities can occur, although most patients have only sensory symptoms and signs. Sensory findings in the hands are more commonly associated with drug toxicity. HIV-related DSPN may evolve from painful to painless numbness.",
"   </p>",
"   <p>",
"    The presence of brisk knee reflexes in patients with sensory loss raises the possibility of coexistent myelopathy, while the presence of proximal weakness or diffuse areflexia should prompt consideration of acquired inflammatory demyelinating polyradiculoneuropathy, such as Guillain-Barre syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of peripheral neuropathy syndromes in HIV-infected patients is based mainly upon the clinical picture and physical examination.",
"   </p>",
"   <p>",
"    Features that would prompt further evaluation, such as electromyography (EMG) and nerve conduction studies (NCS), may include significant weakness or asymmetry of signs. These findings may raise the possibility of alternative diagnoses (eg, acquired demyelinating polyradiculoneuropathy or vasculitic neuropathy). (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Other modalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of distal symmetrical polyneuropathy should include blood work to screen for other causes of this type of neuropathy. A typical panel would include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hepatitis C antibody",
"     </li>",
"     <li>",
"      Vitamin B12 and folate levels",
"     </li>",
"     <li>",
"      Thyroid stimulating hormone assay",
"     </li>",
"     <li>",
"      Blood glucose",
"     </li>",
"     <li>",
"      Blood urea nitrogen and creatinine",
"     </li>",
"     <li>",
"      Serum protein electrophoresis and immunoelectrophoresis",
"     </li>",
"     <li>",
"      RPR",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these laboratory tests are considered routine in the evaluation of DSPN, they are usually unremarkable in HIV-related or drug-induced polyneuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other testing modalities include a subjective peripheral neuropathy screening test, electrodiagnostic studies, skin biopsy for epidermal nerve fiber density analysis, and nerve biopsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrodiagnostic studies show a sensorimotor polyneuropathy, which is predominantly axonal [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/1\">",
"       1",
"      </a>",
"      ]. Nerve conduction studies usually confirm a length-dependent axonal polyneuropathy, distinguishing DSPN from acquired inflammatory demyelinating neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link\">",
"       \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin biopsy for epidermal nerve fiber density analysis has been shown to correlate with neuropathy severity, level of neuropathic pain, and sensory amplitudes on electrodiagnostic studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/55\">",
"       55",
"      </a>",
"      ]. An abnormal skin biopsy predicts conversion to symptomatic DSPN in patients with no or asymptomatic neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/56\">",
"       56",
"      </a>",
"      ]. Skin biopsy can be positive, whereas electrodiagnostic studies may be negative, in patients with predominantly small nerve fiber involvement and thus can be a useful confirmatory test for early or predominantly small fiber DSPN.",
"     </li>",
"     <li>",
"      Nerve biopsy is not usually required but occasionally is performed in severe cases to exclude a confluent presentation of mononeuropathy multiplex. Biopsies show axonal loss with frequent foci of inflammation in the endoneurium or around perineurial blood vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/27,37,39,57\">",
"       27,37,39,57",
"      </a>",
"      ]. The severity of cases is judged clinically (eg, significant weakness on examination) and by electrodiagnostic tests (eg, significant axon loss). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link\">",
"       \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for HIV-related and drug-induced distal symmetrical polyneuropathy are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Potential interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of HAART on the severity of distal symmetrical polyneuropathy is unclear, although there is some evidence showing improved quantitative sensory measures in patients responding to HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. If a potentially neurotoxic drug is being used, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (d4T), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (ddI), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , it should be discontinued whenever possible. There may be a \"coasting phenomenon\" where the neuropathy worsens for one to six weeks following reduction in the dose of a nucleoside analog [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/37,39,40,59\">",
"     37,39,40,59",
"    </a>",
"    ]. Gradual improvement then occurs; the time to recovery depends upon the dose and varies from 3 to 19 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/37,59\">",
"     37,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The experimental agent recombinant human nerve growth factor has been shown to significantly improve pain compared to placebo, although this treatment does not improve neuropathy severity by examination, quantitative sensory testing, and epidermal nerve fiber density. The presence of injection site pain in the treated cohort may have unblinded this study. This experimental agent is not approved by the United States Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since dideoxynucleoside analogs are thought to cause peripheral neuropathy through the disruption of mitochondrial metabolism, there has been interest in using amino acid supplements needed for oxidative pathways. Two small studies of acetyl",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    have suggested clinical benefit, although neither one had a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also important to address any nutritional or metabolic issues that may be contributing to DSPN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Symptomatic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical management of HIV-associated DSPN is often by default based on studies of peripheral neuropathy in other disease states, such as diabetes. Management of polyneuropathy is thus largely symptomatic and is usually aimed at ameliorating the painful dysesthesias. The classes of drugs used include anticonvulsants, tricyclic antidepressants, topical analgesics, anti-inflammatories, and opioids for recalcitrant symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"     \"Overview of polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal processing of impulses from neuronal receptors contributes to neuropathic pain. Thus, a pharmacologic approach will include multiple possible targets with drugs of different classes, as discussed below. There are few data on the use of these agents in HIV-infected patients; most of the existing studies are small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    is widely used in the treatment of neuropathic pain in diabetics and those with trigeminal neuralgia. A placebo-controlled trial in 26 HIV-infected patients with DSPN found gabapentin effective in reducing painful symptoms and sleep disturbance at four weeks of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/64\">",
"     64",
"    </a>",
"    ]. Studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , an agent with a similar mechanism of action as gabapentin, are in progress. Anecdotal reports suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , which is effective in prophylaxis of migraines, may be useful as well; side effects include weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    has been studied in HIV neuropathy patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/66,67\">",
"     66,67",
"    </a>",
"    ] and, in a small, randomized placebo-controlled trial, improved pain more than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/66\">",
"     66",
"    </a>",
"    ]. However, there was a high dropout rate in the lamotrigine group, predominantly due to rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricyclic antidepressants inhibit the reuptake of norepinephrine and serotonin into the presynaptic neurons and thereby block nociceptive receptors. The use of tricyclic antidepressants for HIV-associated DSPN is also based upon their efficacy in other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, two double-blind trials in HIV-infected patients found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    was no better than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since these trials were small and had only short-term follow-up, many clinicians still use antidepressants in HIV-infected patients with DSPN based on their effectiveness in other populations. Options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    (starting at 10 mg at bedtime and increase as tolerated to 75 to 100 mg based on symptomatic improvement). Other potential agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (37.5 to 225",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    (the active ingredient in hot chili peppers) are applied directly over the affected painful site. Capsaicin's mechanism of action may involve desensitization of peripheral endings of cutaneous afferent neurons. An open-label study of a single 60-minute application of an experimental, high-dose capsaicin dermal patch showed a 40 percent reduction in pain scale scores from two to 12 weeks post-application [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/70\">",
"     70",
"    </a>",
"    ]. A subsequent placebo-controlled trial had more modest reductions in pain relief (23 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/71\">",
"     71",
"    </a>",
"    ]. The doses used in this study are not available for clinical use.",
"   </p>",
"   <p>",
"    In a double-blind, placebo-controlled trial assessing the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    gel compared to placebo demonstrated that lidocaine was safe but ineffective against symptoms of peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/72\">",
"     72",
"    </a>",
"    ]. However, in a double-blind, multicenter study that randomized 307 subjects with DSPN to an investigational high-concentration versus a low concentration",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    dermal patch, those randomly assigned the high concentration patch had a greater reduction of pain intensity over a 12 week period (23 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Anti-inflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-steroidal anti-inflammatory agents are not very effective for pain control and their chronic administration can be associated with adverse events, such as exacerbation of underlying renal disease secondary to HIV associated nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Narcotic analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    (50 to 100 mg three times daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    patch may need to be added to the above mentioned therapies for breakthrough pain or to control recalcitrant symptoms. Dosage should be gradually titrated to alleviate symptoms. Chronic administration can lead to dependence and tolerance, which are predictable physiologic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/74\">",
"     74",
"    </a>",
"    ]. In contrast, addiction is defined as a long-term compulsive use of a substance in spite of harm. Clinicians need to be aware of this distinction when prescribing long-term use of narcotics. Written patient-doctor contracts regarding opioid use are often helpful; referral to a pain specialist for evaluation is suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoked cannabis has been shown to reduce daily pain from DSPN by 34 percent compared with placebo cigarettes with the cannabinoids extracted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/75\">",
"     75",
"    </a>",
"    ]. No serious adverse events were reported.",
"   </p>",
"   <p>",
"    Acupuncture was no more efficacious than placebo in one study of 250 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/69\">",
"     69",
"    </a>",
"    ]. Mexilitene has also been evaluated in two studies but was ineffective in relieving symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/68,76\">",
"     68,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The polypeptide, prosaptide, was ineffective in improving pain compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/77\">",
"     77",
"    </a>",
"    ]. The NMDA antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    , has also been shown to be ineffective compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29577/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal symmetric polyneuropathy (DSPN) is the most common neurologic manifestation in HIV-infected patients. Risk factors for DSPN include advanced immunosuppression, level of HIV viremia, aging, diabetes, and nutritional deficiencies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain antiretroviral agents are associated with DSPN, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DSPN usually manifests as bilateral tingling, and numbness in the lower extremities. Neuropathic pain is common and may be the presenting symptom. Neurologic examination demonstrates sensory loss to all sensory modalities in a stocking distribution with reduced or absent deep tendon reflexes at the ankles. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of peripheral neuropathy syndromes in HIV-infected patients is based upon the clinical picture and physical examination. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with features that suggest an alternative diagnosis, such as significant weakness or asymmetry of signs, should undergo electromyography (EMG) and nerve conduction studies (NCS). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who are being evaluated for DSPN should have laboratory testing for",
"      <span class=\"nowrap\">",
"       B12/folate,",
"      </span>",
"      thyroid stimulating hormone assay, random glucose, creatinine, serum protein electrophoresis and immunoelectrophoresis, hepatitis C antibody, and RPR. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for HIV-related and drug-induced distal symmetrical polyneuropathy are limited. Antiretroviral agents that are associated with DSPN (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      ) should be discontinued. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of DSPN is thus largely symptomatic and is usually aimed at ameliorating the painful dysesthesias. We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      for initial treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If ineffective, we recommend choosing a second-line therapy based on a patient's comorbidities. Options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      in patients with obesity or recurrent migraines, antidepressants, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      , for those with concomitant depression, and topical agents for those intolerant of systemic medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For breakthrough pain, topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      and opioid medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      , may be helpful. For recalcitrant symptoms, evaluation by a pain specialist and chronic opioid therapy may be considered.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/1\">",
"      Ferrari S, Vento S, Monaco S, et al. Human immunodeficiency virus-associated peripheral neuropathies. Mayo Clin Proc 2006; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/2\">",
"      Kolson DL, Gonz&aacute;lez-Scarano F. Human immunodeficiency virus-associated distal sensory polyneuropathy: still common after many successes. Arch Neurol 2010; 67:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/3\">",
"      So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol 1988; 45:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/4\">",
"      Schifitto G, McDermott MP, McArthur JC, et al. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002; 58:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/5\">",
"      Lichtenstein KA, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 2005; 40:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/6\">",
"      Cherry CL, Skolasky RL, Lal L, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology 2006; 66:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/7\">",
"      Maschke M, Kastrup O, Esser S, et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000; 69:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/8\">",
"      Simpson DM, Kitch D, Evans SR, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006; 66:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/9\">",
"      Barohn RJ, Gronseth GS, LeForce BR, et al. Peripheral nervous system involvement in a large cohort of human immunodeficiency virus-infected individuals. Arch Neurol 1993; 50:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/10\">",
"      Simpson DM, Katzenstein DA, Hughes MD, et al. Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. AIDS 1998; 12:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/11\">",
"      Dalakas MC, Pezeshkpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988; 23 Suppl:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/12\">",
"      Lange DJ, Britton CB, Younger DS, Hays AP. The neuromuscular manifestations of human immunodeficiency virus infections. Arch Neurol 1988; 45:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/13\">",
"      Miller RG, Parry GJ, Pfaeffl W, et al. The spectrum of peripheral neuropathy associated with ARC and AIDS. Muscle Nerve 1988; 11:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/14\">",
"      Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/15\">",
"      Simpson DM, Haidich AB, Schifitto G, et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 2002; 16:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/16\">",
"      Schifitto G, McDermott MP, McArthur JC, et al. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005; 64:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/17\">",
"      Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004; 61:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/18\">",
"      Ances BM, Vaida F, Rosario D, et al. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 2009; 23:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/19\">",
"      Clifford DB, Smurzynski M, Park LS, et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 2009; 73:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/20\">",
"      Malessa R, Agelink M, Himmelmann M, et al. Nerve conduction changes in asymptomatic HIV-1 seropositive individuals in the absence of other risk factors for neuropathy. Electromyogr Clin Neurophysiol 1996; 36:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/21\">",
"      Ronchi O, Grippo A, Ghidini P, et al. Electrophysiologic study of HIV-1 + patients without signs of peripheral neuropathy. J Neurol Sci 1992; 113:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/22\">",
"      Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999; 56:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/23\">",
"      Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011; 25:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/24\">",
"      Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002; 8 Suppl 2:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/25\">",
"      Lichtenstein KA, Armon C, Buchacz K, et al. Initiation of antiretroviral therapy at CD4 cell counts &gt;/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/26\">",
"      Brinley FJ Jr, Pardo CA, Verma A. Human immunodeficiency virus and the peripheral nervous system workshop. Arch Neurol 2001; 58:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/27\">",
"      de la Monte SM, Gabuzda DH, Ho DD, et al. Peripheral neuropathy in the acquired immunodeficiency syndrome. Ann Neurol 1988; 23:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/28\">",
"      Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985; 313:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/29\">",
"      Chaunu MP, Ratinahirana H, Raphael M, et al. The spectrum of changes on 20 nerve biopsies in patients with HIV infection. Muscle Nerve 1989; 12:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/30\">",
"      Rizzuto N, Cavallaro T, Monaco S, et al. Role of HIV in the pathogenesis of distal symmetrical peripheral neuropathy. Acta Neuropathol 1995; 90:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/31\">",
"      Melli G, Keswani SC, Fischer A, et al. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated sensory neuropathy. Brain 2006; 129:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/32\">",
"      Bradley WG, Shapshak P, Delgado S, et al. Morphometric analysis of the peripheral neuropathy of AIDS. Muscle Nerve 1998; 21:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/33\">",
"      Yoshioka M, Bradley WG, Shapshak P, et al. Role of immune activation and cytokine expression in HIV-1-associated neurologic diseases. Adv Neuroimmunol 1995; 5:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/34\">",
"      Keswani SC, Polley M, Pardo CA, et al. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003; 54:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/35\">",
"      Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005; 10 Suppl 2:M47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/36\">",
"      Hahn K, Triolo A, Hauer P, et al. Impaired reinnervation in HIV infection following experimental denervation. Neurology 2007; 68:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/37\">",
"      Berger AR, Arezzo JC, Schaumburg HH, et al. 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993; 43:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/38\">",
"      Blum AS, Dal Pan GJ, Feinberg J, et al. Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors. Neurology 1996; 46:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/39\">",
"      Kieburtz KD, Seidlin M, Lambert JS, et al. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J Acquir Immune Defic Syndr 1992; 5:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/40\">",
"      Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/41\">",
"      Scarsella A, Coodley G, Shalit P, et al. Stavudine-associated peripheral neuropathy in zidovudine-na&iuml;ve patients: effect of stavudine exposure and antiretroviral experience. Adv Ther 2002; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/42\">",
"      Peltier AC, Russell JW. Advances in understanding drug-induced neuropathies. Drug Saf 2006; 29:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/43\">",
"      Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab Invest 2001; 81:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/44\">",
"      McComsey G, Lonergan JT. Mitochondrial dysfunction: patient monitoring and toxicity management. J Acquir Immune Defic Syndr 2004; 37 Suppl 1:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/45\">",
"      Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994; 38:1824.",
"     </a>",
"    </li>",
"    <li>",
"     Hulgan, T, Hughes, M, Sun, X, et al. Oxidant Stress and Peripheral Neuropathy During Antiretroviral Therapy: An AIDS Clinical Trials Group Study. J Acquir Immune Defic Syndr 2006;.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/47\">",
"      Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/48\">",
"      Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 2005; 19:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/49\">",
"      Kallianpur AR, Hulgan T, Canter JA, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006; 20:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/50\">",
"      Pettersen JA, Jones G, Worthington C, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 2006; 59:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/51\">",
"      Ellis RJ, Marquie-Beck J, Delaney P, et al. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 2008; 64:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/52\">",
"      Wallace DC. Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci U S A 1994; 91:8739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/53\">",
"      Canter JA, Robbins GK, Selph D, et al. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis 2010; 201:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/54\">",
"      Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/55\">",
"      Zhou L, Kitch DW, Evans SR, et al. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy. Neurology 2007; 68:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/56\">",
"      Herrmann DN, McDermott MP, Sowden JE, et al. Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study. Neurology 2006; 66:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/57\">",
"      Martin C, Solders G, S&ouml;nnerborg A, Hansson P. Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 2000; 54:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/58\">",
"      Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy. N Engl J Med 1999; 340:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/59\">",
"      Dubinsky RM, Yarchoan R, Dalakas M, Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC). Muscle Nerve 1989; 12:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/60\">",
"      McArthur JC, Yiannoutsos C, Simpson DM, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000; 54:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/61\">",
"      Schifitto G, Yiannoutsos C, Simpson DM, et al. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology 2001; 57:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/62\">",
"      Herzmann C, Johnson MA, Youle M. Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials 2005; 6:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/63\">",
"      Osio M, Muscia F, Zampini L, et al. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst 2006; 11:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/64\">",
"      Hahn K, Arendt G, Braun JS, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004; 251:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/65\">",
"      Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002; 59:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/66\">",
"      Simpson DM, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 2000; 54:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/67\">",
"      Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003; 60:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/68\">",
"      Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 51:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/69\">",
"      Shlay JC, Chaloner K, Max MB, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998; 280:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/70\">",
"      Simpson DM, Estanislao L, Brown SJ, Sampson J. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage 2008; 35:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/71\">",
"      Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/72\">",
"      Estanislao L, Carter K, McArthur J, et al. A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 2004; 37:1584.",
"     </a>",
"    </li>",
"    <li>",
"     Simpson, D, Brown, S, Chang, S, et al. Controlled study of high-concentration capsaicin patch for painful HIV-associated distal sensory polyneuropathy. Presented at the 13th annual Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8th, 2006; abstract #79.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/74\">",
"      Verma S, Estanislao L, Mintz L, Simpson D. Controlling neuropathic pain in HIV. Curr HIV/AIDS Rep 2004; 1:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/75\">",
"      Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/76\">",
"      Kemper CA, Kent G, Burton S, Deresinski SC. Mexiletine for HIV-infected patients with painful peripheral neuropathy: a double-blind, placebo-controlled, crossover treatment trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/77\">",
"      Evans SR, Simpson DM, Kitch DW, et al. A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One 2007; 2:e551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29577/abstract/78\">",
"      Schifitto G, Yiannoutsos CT, Simpson DM, et al. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 2006; 12:328.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3711 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29577=[""].join("\n");
var outline_f28_56_29577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect of antiretroviral therapy on natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Dideoxynucleosides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Host genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Potential interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Symptomatic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Topical agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Narcotic analgesics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=related_link\">",
"      Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_56_29578="Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome";
var content_f28_56_29578=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninvasive imaging and stress testing in patients with suspected acute coronary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29578/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29578/contributors\">",
"     Prem Soman, MD, PhD, FACC, FRCP (UK)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29578/contributors\">",
"     Quynh A Truong, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29578/contributors\">",
"     James E Udelson, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29578/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29578/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29578/contributors\">",
"     Jeroen J Bax, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/56/29578/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/56/29578/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/56/29578/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triage of patients presenting to the emergency department (ED) with chest pain poses a unique challenge to physicians. On one hand, less than a third of the six to eight million annual presentations to the ED with chest pain are eventually diagnosed with coronary artery disease (CAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/1\">",
"     1",
"    </a>",
"    ]. On the other hand, 2 to 4 percent of patients with an acute coronary syndrome (ACS which includes acute myocardial infarction [AMI] and unstable angina) are inadvertently discharged home. The potentially adverse consequences of missing a diagnosis of ACS has resulted in the current practice paradigm of admitting these patients for prolonged ED or inpatient observation and testing at a cost estimated to be several billion dollars in the United States annually [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of noninvasive imaging and stress testing to risk stratify patients presenting with possible acute coronary syndrome is discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND ITS LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation and biomarker testing are helpful in classifying patients as having a low, intermediate or high likelihood of ACS secondary to CAD (",
"    <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"     table 1",
"    </a>",
"    ) and identifying features associated with risk of AMI and death (",
"    <a class=\"graphic graphic_table graphicRef65662 \" href=\"UTD.htm?19/21/19805\">",
"     table 2",
"    </a>",
"    ). The initial evaluation and management is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=see_link\">",
"     \"Evaluation of chest pain in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=see_link\">",
"     \"Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the presenting history, physical examination and 12-lead electrocardiogram (ECG) generally have limited diagnostic sensitivity and specificity for the diagnosis of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Only a minority of patients present with typical anginal pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ECG changes diagnostic of ACS. While a completely normal ECG is associated with a lower risk for cardiac events, its negative predictive value is limited and generally fewer than 20 percent of patients have a normal ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Many patients have baseline ECG changes such as hypertrophy, bundle branch block, ventricular pacing, or non-specific ST or T wave changes that preclude the diagnosis of ischemia. The sensitivity of the initial ECG in patients eventually diagnosed with ACS is only about 50 percent. Even a normal ECG during chest pain has limited negative predictive value for exclusion of ACS. In a report of 387 patients presenting with chest pain with a normal ECG, the frequency of ACS was similar whether or not chest pain was present during the ECG (16 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although elevations in serum cardiac troponins T and I are sensitive and specific for AMI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/7\">",
"     7",
"    </a>",
"    ], disadvantages of troponin testing include the requirement for serial measurements as well as inability to detect ACS without myocardial necrosis (ie, unstable angina). Serial measurements are required to identify those patients whose troponins will become elevated only hours after presentation. For example, in a large series of patients with suspected acute coronary syndrome, 68 percent of patients who were troponin T negative on presentation had a positive result on a later sample [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/8\">",
"     8",
"    </a>",
"    ]. In the Diagnostic Marker Cooperative Study for the Diagnosis of Myocardial Infarction, in which serial blood sampling was performed every two hours, the maximum sensitivity for the diagnosis of AMI was obtained with the 10-hour sample of troponin T and I [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/9\">",
"     9",
"    </a>",
"    ]. The need for serial sampling to obtain maximum sensitivity results in delays in the triage decision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the limitations of initial evaluation and biomarker testing, additional noninvasive testing strategies have been evaluated for early identification of ACS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RATIONALE FOR NONINVASIVE TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Myocardial perfusion and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sequence of pathophysiologic events (termed the ischemic cascade) follows the onset of myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When myocardial oxygen demand exceeds supply (due to either increased oxygen demand or reduced supply), the first abnormality detected is regional myocardial blood flow heterogeneity between the vascular beds supplied by normal and stenosed coronary arteries. This manifests as a regional perfusion defect on myocardial perfusion imaging.",
"     </li>",
"     <li>",
"      Left ventricular relaxation abnormalities manifesting as diastolic dysfunction occur next, but the clinical utility of identification of diastolic dysfunction for the diagnosis of ACS has not been established.",
"     </li>",
"     <li>",
"      Regional systolic dysfunction (manifest as regional wall motion abnormalities) follows the relaxation abnormality and is highly specific for regional ischemia.",
"     </li>",
"     <li>",
"      Electrocardiographic changes of myocardial ischemia and anginal symptoms (chest pain) are late events in the ischemic cascade.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since regional flow heterogeneity and systolic dysfunction precede chest pain in the ischemic cascade, the absence of these phenomena in a patient with ongoing chest pain should be reliable evidence of the non-ischemic nature of the chest pain. Noninvasive imaging studies have demonstrated that regional flow heterogeneity has a higher sensitivity for ACS while regional systolic dysfunction has a higher specificity.",
"   </p>",
"   <p>",
"    Both rest imaging and stress testing are helpful in triaging patients with suspected ACS with negative serum cardiac biomarkers and inconclusive ECGs. A rest image during symptoms may be sufficient to detect or exclude flow heterogeneity (radionuclide myocardial perfusion imaging) or regional wall thickening abnormalities (echocardiography). However, if symptoms have abated, then provocative stress testing may be necessary to exclude obstructive coronary artery disease as the etiology of chest pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Noninvasive coronary imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternate approach to functional imaging is direct visualization of the coronary artery tree to detect obstructive CAD by noninvasive coronary imaging using coronary computed tomographic angiography (CCTA). With this approach, the absence of obstructive CAD in a patient with chest pain is used to exclude ACS.",
"   </p>",
"   <p>",
"    Although some studies have defined ACS as the presence of suggestive symptoms (chest pain or equivalent) with an unstable pattern plus significant (&gt;50 percent) coronary artery stenosis, a causal relationship between symptoms and CAD may not be established by coronary imaging alone. In patients with chest pain and known CAD, or in chest pain patients found to have intermediate degrees of coronary stenosis, functional testing may be required to establish or exclude myocardial ischemia as the cause of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link&amp;anchor=H14#H14\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\", section on 'Test methodology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     REST IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four major imaging modalities for rest imaging are available to evaluate patients presenting to the ED with possible ACS: two well-established methods, radionuclide myocardial perfusion imaging (rMPI) and echocardiography, and two emerging modalities, coronary computed tomographic angiography (CCTA) and cardiovascular magnetic resonance (CMR).",
"   </p>",
"   <p>",
"    Rest imaging may be less helpful in diagnosing ACS in patients with prior MI since the age of abnormalities may be uncertain unless a significant new defect is present and a prior study is available for comparison.",
"   </p>",
"   <p>",
"    A low risk patient (",
"    <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"     table 1",
"    </a>",
"    ) with negative rest imaging test can be managed as an outpatient if clinically stable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Rest myocardial perfusion imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rest radionuclide myocardial perfusion imaging (rMPI) provides diagnostic and prognostic information useful for the ED triage of chest pain patients. The 2003 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Society of Nuclear Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ASNC)",
"    </span>",
"    Guidelines for the Clinical Use of Cardiac Radionuclide Imaging recommended use of rest rMPI in the assessment of myocardial risk in possible ACS patients with nondiagnostic ECG and initial serum markers and enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/11\">",
"     11",
"    </a>",
"    ]. The 2009 Appropriate Use Criteria for Cardiac Radionuclide imaging rated resting rMPI as appropriate in patients with possible ACS with no ECG changes or LBBB or ventricular paced rhythm with initial troponin negative and recent or ongoing chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of rMPI in this setting is supported by observational as well as randomized clinical trial data. Based on the pathophysiology of the ischemic cascade, rMPI is expected to have a high diagnostic sensitivity for obstructive CAD resulting in ischemia in patients with acute chest pain, and this has been borne out by clinical data (",
"    <a class=\"graphic graphic_table graphicRef60669 \" href=\"UTD.htm?28/46/29421\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3496?source=see_link\">",
"     \"Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    rMPI is helpful in stratifying risk in patients presenting with chest pain, as well as in diagnosing the presence of ACS due to CAD, so that further management decisions are informed by an estimate of risk of subsequent adverse cardiac events (",
"    <a class=\"graphic graphic_table graphicRef73446 \" href=\"UTD.htm?0/30/493\">",
"     table 4",
"    </a>",
"    ). The predictive value of rMPI for clinical outcomes is an additional rationale for use of rMPI beyond its diagnostic performance for detection of ACS, which varies depending on the gold standard used for diagnosis of ACS. Several studies have demonstrated that a low incidence of cardiac death or nonfatal myocardial infarction in patients with chest pain and a normal rest rMPI in the ED setting followed for up to 18 months.",
"   </p>",
"   <p>",
"    These data indicate that patients with acute chest pain and a normal rest rMPI can be safely discharged from the ED. It must be emphasized that the lowest event rates are associated with scans that are completely normal. Equivocal scans are associated with event rates which are intermediate between those associated with normal and clearly abnormal scans (",
"    <a class=\"graphic graphic_table graphicRef73446 \" href=\"UTD.htm?0/30/493\">",
"     table 4",
"    </a>",
"    ). Thus the interpretation of rMPI in ED patients should be geared towards obtaining maximum sensitivity for potential disease by identifying and reporting any abnormality as significant.",
"   </p>",
"   <p>",
"    While the above observational studies assessed the diagnostic and prognostic performance of rest rMPI, one large and one small randomized clinical trial demonstrated its clinical effectiveness by showing that use of a triage strategy incorporating rest rMPI resulted in a larger number of patients without ACS being appropriately discharged from the ED compared to a strategy of standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/13\">",
"     13",
"    </a>",
"    ], and that use of rest rMPI was associated with shorter hospital stay and lower costs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3496?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome\", section on 'Use in emergency department triage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One limitation of rMPI is the confounding influence of soft tissue attenuation artifacts. In the ED setting in which only one set of images is acquired, gating is less useful to differentiate attenuation artifacts from true perfusion defects. However, use of gated images for assessment of LV function with rest rMPI improved its predictive power [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/15\">",
"     15",
"    </a>",
"    ]. The application of quantitative attenuation correction programs is likely to be useful in this setting but has not been formally tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Choice of tracer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tc-99m tracers rather than thallium imaging is recommended for acute rest rMPI. Initial studies were performed with planar thallium-201 imaging techniques which are limited by rapid redistribution so image acquisition must be performed within minutes after tracer injection. Subsequent technical improvements included use of single photon emission computed tomography (SPECT) with Tc-99m sestamibi or tetrofosmin. With Tc-99m tracers, image acquisition can be delayed for up to two hours after tracer injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3496?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome\", section on 'Detection of ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Timing of injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the sensitivity of resting rMPI may diminish after symptom resolution, it is recommended that radionuclide tracer injection be performed during symptoms or within two hours of symptom resolution as recommended in the American Society of Nuclear Cardiology (ASNC) position statement on radionuclide imaging for suspected ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A limitation of tests assessing resting regional perfusion or function is that sensitivity for ACS is highest when the test is performed during active symptoms and progressively diminishes after symptom resolution. This is an important consideration in evaluation of ED patients who frequently present when symptoms have resolved. Evidence suggests that while regional dysfunction frequently resolves within minutes after resolution of ischemic symptoms, perfusion abnormalities may persist longer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Tl-201 study found that sensitivity for detecting ischemia diminished as time increased beyond six hours from the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/18\">",
"     18",
"    </a>",
"    ]. In another study, perfusion abnormalities were detected in 65 percent of patients injected more than four hours after the episode of chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/19\">",
"     19",
"    </a>",
"    ]. Similarly, myocardial perfusion imaging demonstrated preserved (100%) diagnostic sensitivity for ACS when Tc-99m sestamibi injection was delayed for up to three to four hours after symptom resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Timing of rest rMPI may also be a factor in comparing the sensitivity and specificity of rest rMPI with stress rMPI. When rest rMPI is not timed to coincide with chest pain, stress rMPI may have greater sensitivity and specificity for detection of ACS. This possibility was suggested by a study of 805 low-risk possible ACS patients with negative two-hour evaluation including serial ECGs and biomarkers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/21\">",
"     21",
"    </a>",
"    ]. Stress (exercise or pharmacologic) rMPI was more sensitive (97 versus 71 percent) and specific (88 versus 73 percent) than rest rMPI for 30-day ACS (AMI, coronary revascularization or significant coronary stenosis, life-threatening complication or cardiac death). The timing of rest rMPI in relation to time of chest pain was not reported.",
"   </p>",
"   <p>",
"    On the other hand, similar sensitivities and specificities for rest and exercise rMPI were observed in an ED study in which rest rMPI was performed in patients presenting &lt;3 hours after onset of chest pain and stress rMPI was performed in patients presenting &ge;3 hours after onset of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/22\">",
"     22",
"    </a>",
"    ]. The sensitivities for detection of CAD for rest and exercise rMPI were 94 and 95 percent and the specificities were 75 and 83 percent. A limitation of this study is that rest and stress rMPI were not performed in the same patients.",
"   </p>",
"   <p>",
"    Experimental evidence of persistence of perfusion defects for a substantial period of time after ischemia resolution comes from a study of patients undergoing PCI as a model of \"supply\" type ischemia consistent with what occurs in ACS. Perfusion defects on Tc-99m sestamibi imaging were observed in all patients undergoing coronary angioplasty during balloon inflation and in 70 percent, 37 percent, and 19 percent of patients re-injected 15 minutes, 1-3 hours and 24 hours after balloon deflation, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, clinical and experimental observations suggest that perfusion abnormalities may persist for several hours after resolution of ischemia and associated symptoms although sensitivity is greatest during ischemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rest two-dimensional echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with rMPI, fewer data are available to support the use of other noninvasive imaging modalities in the evaluation of possible ACS. Two-dimensional echocardiography has been shown to have high sensitivity for the diagnosis of AMI (93 percent) and ACS ( 88 percent), and moderate specificity for AMI (78 percent) and ACS (53 percent) using regional dysfunction as the criteria for abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/23-27\">",
"     23-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 1997",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for clinical application of echocardiography recommend echocardiography in the evaluation of chest pain in patients with suspected acute myocardial ischemia when the ECG is nondiagnostic and when the study can be obtained during or soon after pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/28\">",
"     28",
"    </a>",
"    ]. Similarly, the 2011 Appropriateness Criteria for Echocardiography rated resting echocardiography performed during pain as appropriate in the evaluation of acute chest pain with suspected myocardial infarction in patients with nondiagnostic ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/29\">",
"     29",
"    </a>",
"    ]. The criteria also rated as appropriate the performance of echocardiography in a patient without chest pain but with other features of an ischemic equivalent or laboratory markers indicative of ongoing myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of echocardiography in acute myocardial infarction\", section on 'Diagnosis of MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of note, the performance characteristics of echocardiography are less optimal for the detection of ACS compared to AMI, while the ED physician faced with a decision on patient disposition is interested in identifying all ACS including unstable angina as well as AMI.",
"   </p>",
"   <p>",
"    The predictive value of resting echocardiography within four hours of ED presentation was demonstrated in a study of 260 patients presenting to the ED with possible ACS found that rest echocardiography predicted cardiac events (including AMI and revascularization) with 91 percent sensitivity and 75 percent specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/26\">",
"     26",
"    </a>",
"    ]. When patients with abnormal ECGs were excluded, the sensitivity and specificity of rest echocardiography for predicting cardiac events was similar (85 and 74 percent respectively). Other studies indicate that echocardiography performed after resolution of symptoms is unlikely to predict cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of contrast agents can enhance endocardial detection for assessment of regional wall motion. Use of contrast agents to assess myocardial perfusion has also been investigated (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H27\">",
"     'Myocardial contrast echocardiography'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Limited data directly compare rest rMPI and rest echocardiography in patients presenting with acute chest pain. A study of 470 patients classified as having low to moderate risk of ACS found that rest rMPI and rest echocardiography had similar sensitivities and specificities for prediction of AMI or coronary intervention (sensitivity 100 percent for both; specificity 89 percent for rMPI and 86 percent for echocardiography) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/31\">",
"     31",
"    </a>",
"    ]. Rest rMPI and rest echocardiography also performed similarly for prediction of AMI, significant coronary artery stenosis, or positive stress rMPI (sensitivity 75 percent for both; specificity 88 percent for echocardiography and 90 percent for rMPI).",
"   </p>",
"   <p>",
"    A potential advantage of use of echocardiography in the ED setting is its ability to detect complications of MI as well as evidence of other causes of acute chest pain such as proximal aortic dissection, acute pericarditis, stress-induced cardiomyopathy and large pulmonary embolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coronary computed tomographic angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incorporating coronary computed tomography angiography (CCTA) into an early evaluation strategy in patients presenting with suspected ACS who warrant noninvasive testing may facilitate triage decisions and shorten lengths of stay while increasing the rates of invasive coronary angiography and revascularization. These effects were demonstrated by a meta-analysis of four randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/32-35\">",
"     32-35",
"    </a>",
"    ] with a total of 3266 low-to-intermediate risk patients comparing 64-slice CCTA to usual care triage of acute chest pain in the ED [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients were followed for six months in two trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/32,33\">",
"     32,33",
"    </a>",
"    ] and for one month in two trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. There were no deaths. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were few MIs (1.3 percent overall) with most occurring during the index hospitalization. Rates of MI, return ED visits, and recurrent hospitalization for cardiovascular causes were similar in CCTA and UC arms.",
"     </li>",
"     <li>",
"      Average LOC was significantly reduced with CCTA compared to UC in all four studies.",
"     </li>",
"     <li>",
"      CCTA significantly increased invasive coronary angiography (8.4 versus 6.3 percent) and revascularization (PCI or CABG) (4.6 versus 2.6 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ACRIN PA and ROMICAT II trials were the largest studies included in the above meta-analysis. The ACRIN-PA multicenter trial randomly assigned 1370 low-to-intermediate risk patients presenting with possible ACS to CCTA or traditional care [",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/noninvasive-imaging-and-stress-testing-in-patients-with-suspected-acute-coronary-syndrome/abstract/35\">",
"     35",
"    </a>",
"    ]. With CCTA as compared to traditional care, lengths of stay were shorter (median 18.0 versus 24.8 hours), rates of discharge from the emergency department were higher (49.6 versus 22.7 percent), and there was a higher rate of detection of coronary disease (9 versus 3.5 percent). One percent of patients in each group had a myocardial infarction within 30 days after presentation and there were no cardiac deaths in either group.",
"   </p>",
"   <p>",
"    The multicenter ROMICAT II trial randomly assigned 1000 low-to-intermediate risk patients presenting to an emergency department with possible ACS to CCTA or standard evaluation [",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/noninvasive-imaging-and-stress-testing-in-patients-with-suspected-acute-coronary-syndrome/abstract/36\">",
"     36",
"    </a>",
"    ]. With CCTA as compared to standard care, lengths of stay were shorter (mean 23.2 versus 30.8 hours) and direct emergency department discharge rates were higher (47 versus 12 percent) without increase in the rate in missed ACS (none in either group). In the CCTA group, more diagnostic testing was performed and cumulative radiation exposure was higher. Per-patient costs for the ED episode of care were lower than with standard care (mean $2053 versus $2532), but costs were similar out to 30 days of follow-up.",
"   </p>",
"   <p>",
"    An earlier meta-analysis of nine observational studies with a total of 1559 low to intermediate risk patients presenting with possible ACS evaluated the accuracy of 64-slice coronary CT in predicting major adverse cardiac events (MACE, defined as myocardial infarction, coronary revascularization, cardiac arrest, or death from an ACS) at 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/37\">",
"     37",
"    </a>",
"    ]. A positive CCTA (at least 50 percent coronary stenosis) was identified in 14.8 percent of patients. The overall sensitivity and specificity of CCTA for prediction of MACE were 93.3 percent and 89.9 percent. The positive predictive value was 48.1 percent and the negative predictive value was 99.3 percent.",
"   </p>",
"   <p>",
"    In summary, CCTA has strong predictive value in excluding risk of MACE, can facilitate triage decisions, and reduce lengths of stay. Impact of CCTA versus usual care triage on long-term morbidity and mortality has not been determined.",
"   </p>",
"   <p>",
"    <br/>",
"    One consideration is the potential risk associated with radiation exposure from CCTA (or rMPI) which is higher in younger patients and in women as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link&amp;anchor=H9#H9\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\", section on 'Radiation exposure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14376?source=see_link\">",
"     \"Radiation dose and risk of malignancy from cardiovascular imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1327802\">",
"    <span class=\"h3\">",
"     Major society statements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major society statements were published prior to the two latest large randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    unstable",
"    <span class=\"nowrap\">",
"     angina/non-ST",
"    </span>",
"    elevation MI guidelines (with 2011 focused update) suggest that for patients with suspected ACS with a low or intermediate probability of CAD (",
"    <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"     table 1",
"    </a>",
"    ) with normal follow-up ECG and cardiac biomarker measurements, noninvasive coronary imaging (CCTA) is reasonable as an alternative to stress testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 appropriate use criteria classified the use of CCTA as of uncertain appropriateness in intermediate risk patients with acute chest pain of uncertain cause (differential diagnosis including ACS, pulmonary embolus, and aortic dissection) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/39\">",
"     39",
"    </a>",
"    ]. For nonacute symptoms possibly representing an ischemic equivalent, the criteria classified CCTA as appropriate in intermediate risk patients as well as in low risk patients who are unable to exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Coronary artery calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients presenting to the ED with chest pain, those with no CAC have low cardiac event rates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. For example, in a CAC study of 1031 patients presenting to the ED with chest pain, only two events occurred in the 625 patients with no CAC [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/42\">",
"     42",
"    </a>",
"    ]. Similarly, in an earlier electron beam tomography study of 192 patients presenting with chest pain, the 76 patients with no CAC had an annualized cardiovascular event rate of 0.6 percent.",
"   </p>",
"   <p>",
"    However, the use of coronary artery calcium score (CAC) alone to adjudicate chest pain in the ED cannot be recommended at the current time. Although coronary calcification does not occur in the absence of coronary atherosclerosis, the converse is not true. Several studies have established that functionally significant coronary stenosis due to non-calcified plaque can occur with minimal or totally absent coronary calcification, particularly in younger patients with symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data available regarding the use of cardiovascular magnetic resonance (CMR) in ED patients with suspected ACS. The utility of CMR in this setting was explored by a study of 161 patients with suspected ACS and nondiagnostic ECG changes who underwent CMR imaging within 12 hours of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/47\">",
"     47",
"    </a>",
"    ]. Imaging incorporated resting first-pass perfusion analysis, ventricular function, as well as hyperenhancement (but not coronary imaging). Sensitivity and specificity for detecting ACS were 84 percent and 85 percent, respectively, for CMR imaging. In a multivariable analysis, the CMR data were the strongest predictor of the final diagnosis of ACS and added incremental value to the clinical data. A normal CMR study was associated with a high negative predictive value for subsequent cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be incremental value gained by the addition of T2-weighted images and assessment of diastolic left ventricular wall thickness to the protocol above (eg, improvement in specificity for detection of ACS from 84 to 96 percent with unchanged sensitivity of 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/49\">",
"     49",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Coronary magnetic resonance imaging (CMRI) is another potential MR method for identifying coronary artery disease in patients with chest pain. Although multicenter studies have evaluated the accuracy of this method to identify CAD in patients referred for elective invasive coronary arteriography, data are not sufficient to support clinical CMRI for the routine identification of coronary artery stenoses in patients with chest pain at this time.",
"   </p>",
"   <p>",
"    In summary, CMR offers the capability of identifying regional wall abnormalities, perfusion defects, myocardial infarction, and coronary artery disease in a single examination without exposure to ionizing radiation. Its limitations include somewhat limited availability of expertise and facilities to perform comprehensive examinations, length of scan times, contraindication in patients with MR incompatible pacemakers or implantable cardioverter-defibrillators, and limited data to support its use in patients with suspected ACS.",
"   </p>",
"   <p>",
"    Although we do not recommend CMR for routine evaluation of acute chest pain patients, CMR may be helpful in diagnosing particular cases, such as suspected myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Cardiovascular magnetic resonance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     STRESS TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rest perfusion or ventricular function imaging may yield normal results when there is no active myocardial injury although CAD and intermittent ischemia may be present. When resting acute chest pain (or other possible anginal symptoms) have subsided, stress testing is helpful to differentiate between cardiac versus non-cardiac etiologies of pain. Patients may have inducible ischemia due to obstructive coronary artery disease, which may be provoked by physiologic or pharmacologic stress. Safe performance of provocative stress testing requires careful screening to assure that the patient is symptom-free at rest and lacks evidence of myocardial necrosis or resting ischemia by serial cardiac enzymes and ECGs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Patient selection and test timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent with the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    unstable angina and non ST-elevation myocardial infarction guidelines, stress testing (exercise or pharmacologic) is recommended to provoke ischemia in low risk patients (",
"    <a class=\"graphic graphic_table graphicRef65662 \" href=\"UTD.htm?19/21/19805\">",
"     table 2",
"    </a>",
"    ) with suspected ACS after at least SIX to EIGHT hours of observation without recurrent ischemic discomfort if follow-up 12 lead ECG is normal or unchanged from previous tracings and two troponin levels at least six hours apart are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/50\">",
"     50",
"    </a>",
"    ]. A low risk patient (",
"    <a class=\"graphic graphic_table graphicRef65662 \" href=\"UTD.htm?19/21/19805\">",
"     table 2",
"    </a>",
"    ) with a negative stress test can be managed as an outpatient if clinically stable.",
"   </p>",
"   <p>",
"    A limitation of stress testing is that it is unlikely to be helpful if the pre-test probability of CAD is very low. This was illustrated by a study of 220 patients 23 to 40 years of age lacking high risk features for CAD (similar to table 1) (",
"    <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"     table 1",
"    </a>",
"    ). In this population, a combination of age younger than 40 years, nondiagnostic ECG result, and two sets of negative cardiac biomarker results at least six hours apart identified a patient group in which a positive myocardial perfusion imaging stress test was rare (3 percent) and likely to be false positive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/51\">",
"     51",
"    </a>",
"    ]. A discussion of the threshold for evaluation of ACS is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome\", section on 'Threshold for evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Choice of stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of the stress method (exercise or pharmacologic) depends upon the patient's ability to exercise. If a patient is able to exercise, then exercise stress testing is preferred to pharmacological testing since it provides information on the patient's functional capacity. Pharmacologic stress agents include vasodilators (eg, adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , and the newer adenosine A2A-agonists) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    . In the US, vasodilators are generally used in conjunction with rMPI and dobutamine plus atropine is generally used in conjunction with echocardiography. In Europe, vasodilator echocardiography is also performed.",
"   </p>",
"   <p>",
"    The decision as to whether or not the stress test should include imaging as well as 12 lead ECG monitoring depends upon whether the ECG is interpretable for ST changes. Baseline ECG abnormalities that preclude ECG stress test interpretation include preexcitation (Wolff-Parkinson-White) syndrome, a paced ventricular rhythm, more than 1 mm of ST depression at rest, complete left bundle branch block, and patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or with ECG criteria for left ventricular hypertrophy, even if they have less than 1 mm of baseline ST depression. In patients with such abnormalities, an imaging stress test is helpful for diagnosis and prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for noninvasive testing in women with suspected ACS are similar to those for men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/50\">",
"     50",
"    </a>",
"    ]. In women, a stress imaging test may be more predictive of ACS than exercise ECG testing. The predictive value of exercise ECG testing is lower in women than men, primarily due to lower pretest probability of CAD. Stress imaging tests (echocardiography and rMPI) have similar prognostic value in women and men.",
"   </p>",
"   <p>",
"    Choice of stress imaging technique (echocardiography or rMPI) depends upon patient characteristics as well as local expertise and availability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Inpatient or outpatient",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with low risk of ACS, inpatient stress testing is generally preferred. However, early (within 72 hours) outpatient testing is an option in selected patients.",
"   </p>",
"   <p>",
"    An early outpatient stress test evaluation is a reasonable alternative to inpatient testing for the reliable and compliant patient with a low to intermediate pre-test probability for ACS due to CAD (",
"    <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"     table 1",
"    </a>",
"    ) with low risk features (",
"    <a class=\"graphic graphic_table graphicRef65662 \" href=\"UTD.htm?19/21/19805\">",
"     table 2",
"    </a>",
"    ), provided the patients has at least two sets of negative cardiac biomarkers, has no ECG evidence of ischemia on serial ECGs, has physician follow-up, and has an outpatient stress test to be performed within 72 hours which is scheduled prior to ED discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/50,52,53\">",
"     50,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study supporting this approach included 971 patients &ge;40 years old with chest pain with low risk for CAD who underwent outpatient stress testing within 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/53\">",
"     53",
"    </a>",
"    ]. Compliance with outpatient stress testing was 92 percent; no cardiac events (death, MI, or coronary intervention) were observed among those who were not compliant. Among 871 patients with six-month follow-up, 2 percent required coronary intervention, 0.2 percent had an MI, 0.7 percent had normal stress test results after discharge but later required cardiac catheterization, and 0.6 percent returned to the ED for ongoing chest pain. Hospital admission rates decreased significantly from 31 to 26 percent after initiation of the protocol.",
"   </p>",
"   <p>",
"    Outpatient stress testing should NOT be offered to patients at risk for poor compliance since such a strategy may lead to an increased rate of adverse cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As recommended in the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, patients referred for outpatient stress testing should receive precautionary medical therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    beta blockers) while awaiting results of the stress test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Exercise ECG stress test",
"    </span>",
"    &nbsp;&mdash;&nbsp;As recommended in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, when the patient is able to exercise and has a resting ECG that is interpretable for ST-segment changes, exercise ECG stress testing is preferred to imaging stress testing due to its wide availability and low cost [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/50\">",
"     50",
"    </a>",
"    ]. Exercise can be performed using a standard treadmill or supine bike protocol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As summarized in an AHA advisory on exercise testing in ED chest pain centers, studies have demonstrated the safety and utility of symptom-limited treadmill exercise ECG testing after 8 to 12 hours of evaluation in ED patients with low to intermediate risk for CAD (",
"    <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/55\">",
"     55",
"    </a>",
"    ]. A negative exercise stress test makes obstructive coronary artery stenosis highly unlikely given the pre-test probability, particularly if the patient is able to exercise to a good functional capacity. An abnormal exercise treadmill test would warrant admission to the hospital and further workup.",
"   </p>",
"   <p>",
"    The safety and efficacy of exercise ECG testing is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early study of 317 patients with chest pain with low probability of AMI demonstrated that a 12-hour diagnostic protocol including serial CPK-MB, serial ECGs, and exercise ECG had a sensitivity of 90 percent and specificity of 50 percent for diagnosis of ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/56\">",
"       56",
"      </a>",
"      ]. There were no adverse effects of exercise testing.",
"     </li>",
"     <li>",
"      A study of immediate exercise testing of low risk ED chest pain patients indicated that exercise testing was helpful in stratifying cardiovascular events at 30-day follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/57\">",
"       57",
"      </a>",
"      ]. The rate of cardiac event (mortality AMI or revascularization) or diagnosis of CAD was 29 percent in those with a positive test, 13 percent in the nondiagnostic patients, and 0.3 percent in those with negative tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stress imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    unstable",
"    <span class=\"nowrap\">",
"     angina/non-ST",
"    </span>",
"    elevation MI guidelines recommend a pharmacologic stress imaging test for patients with possible ACS and negative cardiac biomarkers who are unable to exercise or have an abnormal resting ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend a pharmacologic stress imaging test for patients with possible ACS and negative cardiac biomarkers who are unable to exercise. We recommend an exercise imaging test for patients with possible ACS with abnormal resting ECG who are able to exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Stress myocardial perfusion imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress radionuclide myocardial perfusion imaging (rMPI) is helpful in the diagnosis and risk stratification of patients presenting with acute chest pain. The 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/ASNC",
"    </span>",
"    Guidelines for the Clinical use of Cardiac Radionuclide Imaging recommended same day",
"    <span class=\"nowrap\">",
"     rest/stress",
"    </span>",
"    rMPI in patients with possible ACS with nondiagnostic ECG and negative serum markers and enzymes OR normal resting scan although evidence for stress testing was emerging at the time of guideline publication. The 2009 Cardiac Radionuclide Appropriateness Criteria rate stress rMPI as appropriate in selected patients with possible (but NOT definite) ACS including those with no ischemic changes or LBBB or ventricular paced rhythm with low or high-risk TIMI score with negative or borderline troponin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stress rMPI offers a higher sensitivity for detection of CAD than exercise ECG testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/22,58\">",
"     22,58",
"    </a>",
"    ]. For example, in a study of 151 low risk ED patients with chest pain, the sensitivity of exercise rMPI (95 percent) was higher than that of exercise ECG (28 percent); the specificities were 83 and 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective observational study of 2074 chest pain patients evaluated by an accelerated protocol including two-hour delta serum CK-MB and troponin I levels, serial ECGs and rest and stress rMPI in those with a negative two-hour evaluation demonstrated high sensitivity (99 percent) and specificity (87 percent) for 30-day ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stress rMPI may be more sensitive than rest rMPI for detection of CAD, particularly when rest rMPI testing does not coincide with chest pain. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Timing of injection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Stress MPI as a component of initial evaluation of acute chest pain may reduce the rate of return chest pain visits. Such a benefit was suggested by a study of 1195 ED chest pain patients with normal or nondiagnostic ECG and at least three negative serial troponin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/60\">",
"     60",
"    </a>",
"    ]. Patients with normal stress rMPI had a lower return visit rate at three months (4 percent) compared to those with abnormal rMPI studies (19 percent), or those with no initial diagnostic evaluation (stress test or cardiac catheterization)(15 percent). In addition, patients who underwent initial diagnostic evaluation had a lower rate of AMI or death in the three-month follow-up period.",
"   </p>",
"   <p>",
"    On the other hand, a study of 1853 patients presenting to the ED with chest pain found that the rate of admission for patients with a normal prior imaging stress test was similar to that for those with no prior stress test [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/61\">",
"     61",
"    </a>",
"    ]. However, no limit was placed on time since the prior stress test (so stress tests performed several years prior were included) and the study did not evaluate the rate of patient return to the ED following prior chest pain evaluation (with or without stress testing).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress echocardiography is an effective modality for identification of CAD in patients presenting with acute chest pain. The 2008 Stress Echocardiography Appropriateness Criteria rated stress echocardiography as appropriate in patients presenting with acute chest pain with intermediate pre-test probability of CAD, no dynamic ECG changes, and negative serial cardiac enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic accuracy of stress echocardiography was evaluated in a study of 503 acute chest pain patients who underwent both exercise stress echocardiography and exercise rMPI for detection of CAD. CAD was defined as &gt;50 percent coronary artery stenosis on angiography or cardiac events (sudden death, nonfatal MI, revascularization) within six months. Stress echocardiography demonstrated similar sensitivity to stress rMPI (85 versus 86 percent), with slightly but significantly greater specificity (95 versus 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/63\">",
"     63",
"    </a>",
"    ]. The sensitivity of exercise ECG was significantly lower (43 percent) although specificity was similar to that for stress echocardiography (95 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    stress echocardiography (DSE) is helpful for risk stratification in patients who are unable to exercise. In a study of 377 low risk ED patients with negative work-up who underwent pre-discharge dobutamine stress echocardiography (DSE), patients with a positive DSE had more than 10-fold risk of cardiac death, myocardial infarction, rehospitalization for unstable angina or revascularization as compared with patients with a negative DSE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preliminary trial suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography may be cost-saving as compared to exercise ECG for early risk stratification of low risk ED chest pain patients. In the trial 199 low risk ED chest pain patients with negative biomarkers and nondiagnostic ECGs were randomly assigned to dobutamine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    stress echocardiography (DSE) or exercise ECG treadmill testing. The DSE strategy resulted in lower costs compared with the exercise ECG strategy at one- and two-month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of ultrasound contrast agents can enhance endocardial detection for assessment of regional wall motion. Use of contrast agents to assess myocardial perfusion has also been investigated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=see_link\">",
"     \"Contrast echocardiography: Contrast agents, safety, and imaging technique\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H27\">",
"     'Myocardial contrast echocardiography'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Stress PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography methods are also available to detect the extent and distribution of coronary artery disease; however, there is scant evidence on their application to patients with ACS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=see_link&amp;anchor=H14#H14\">",
"     \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\", section on 'Positron emission tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Stress CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic (adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ) cardiovascular magnetic resonance (CMR) stress testing has also been used to detect CAD (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Pharmacologic stress CMR'",
"    </a>",
"    ) The utility of stress CMR for evaluation of suspected ACS was suggested by a randomized trial in 109 intermediate risk chest pain patients (median age 56 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The patients were randomly assigned to stress adenosine (or dobutamine) CMR in an observation unit versus standard inpatient care with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CMR group had lower hospitalization costs with 79 percent managed without hospital admission [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/66\">",
"       66",
"      </a>",
"      ]. Also, first-year cardiac-related costs were lower in the CMR group than in the inpatient care group [",
"      <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No patient in either group experienced an ACS within 30 days after discharge. During the year following randomization, rates of major cardiac events were similar in the CMR and inpatient groups (6 and 9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPARISON OF TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several additional considerations apply when choosing a noninvasive modality for the imaging of acute chest pain patients (",
"    <a class=\"graphic graphic_table graphicRef74994 \" href=\"UTD.htm?41/17/42268\">",
"     table 5",
"    </a>",
"    ). Test modalities have varying combinations of availability, portability, and ease of applicability to the ED chest pain population. In addition, a variety of factors impact the quality and breadth of information that the tests provide. For example, echocardiography is widely available, portable, lower cost than nuclear imaging, and does not entail radiation exposure. However, image quality and test interpretability is dependent on the patient's body habitus as well as the skill and expertise of the sonographer and echocardiographer.",
"   </p>",
"   <p>",
"    Radionuclide MPI and CCTA are somewhat more tolerant of variations in body habitus, but require the potentially acutely ill ED patient to cooperate by lying still during image acquisition for rMPI or lying still and performing a timed breath-hold for CCTA. Image quality is critical since the ED physician's decision to triage the patient is frequently dependent upon accurate image interpretation; the inability to visualize even a single segment of the coronary tree in this situation can make a discharge decision difficult.",
"   </p>",
"   <p>",
"    Patient cooperation is particularly crucial for CCTA, since motion or breathing artifacts can invalidate a study that generally cannot be readily reacquired due to contrast and radiation dose considerations. With rMPI, an acquisition affected by patient motion can generally be repeated without additional tracer or radiation burden. Scanner technology (dual-source CT) and algorithms have been developed to perform CCTA in patients with atrial fibrillation or uncontrolled tachycardia who cannot be effectively imaged with single-source CT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential advantage of echocardiography, CCTA, and CMR is that these methods may identify other thoracic causes of chest pain when ACS has been excluded.",
"   </p>",
"   <p>",
"    Considerations for choosing among stress test methods are discussed above (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Choice of stress test'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS FOR ED TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;High diagnostic sensitivity and high negative predictive value for ACS are key attributes for testing strategies to evaluate acute chest pain given the importance of capturing all ACS patients. Since diagnostic sensitivity and specificity vary inversely, this high sensitivity usually comes at the expense of some compromise in diagnostic specificity and positive predictive value.",
"   </p>",
"   <p>",
"    However, a low specificity can result in unnecessary downstream testing, particularly coronary angiography, especially when the test is applied to a population with low prevalence of disease. This is likely to be the case for patients presenting to the ED with chest pain who are referred for noninvasive imaging, since patients with high probability and high risk feature are usually directly referred to coronary angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Myocardial contrast echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonic contrast agents have also been investigated for assessment of myocardial perfusion. While contrast agents for myocardial perfusion are not yet approved by regulatory agencies and have not been widely used for this purpose, published data appear promising. The incremental value of analyzing regional function as well as perfusion using a",
"    <span class=\"nowrap\">",
"     contrast/perfusion",
"    </span>",
"    echo agent was assessed in over 1000 patients presenting to EDs with chest pain and an initially non-diagnostic ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/69\">",
"     69",
"    </a>",
"    ]. The addition of both regional function and perfusion data added value to short- and longer-term prognostication for outcome events. If myocardial perfusion agents are approved, generalizability to less experienced readers will need to be studied, as well as how such prognostic value translates into improvements in clinical decision-making. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link&amp;anchor=H13#H13\">",
"     \"Contrast echocardiography: Clinical applications\", section on 'Myocardial perfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Imaging ischemic memory by (123)I-BMIPP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential future approach to risk stratification in patients who present after resolution of chest pain involves the use of imaging fatty acid metabolism in the aftermath of an episode of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. A radiolabeled iodinated fatty acid analogue 15-(p-[iodine-123] iodophenyl)-3-(R,S) methylpentadecanoic acid (BMIPP) has been used to assess fatty acid utilization in the myocardium. Following an ischemic insult, fatty acid metabolism may be suppressed for a prolonged time period (possibly days), far beyond the time when flow returns to normal and regional tissue ischemia has resolved. Thus, there is potential for imaging the ongoing abnormality in fatty acid metabolism as a signal of \"ischemic memory\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter observational study provided data on the efficacy of BMIPP SPECT imaging in identifying acute coronary syndrome (ACS) in 448 emergency department patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/56/29578/abstract/71\">",
"     71",
"    </a>",
"    ]. The sensitivity of the majority read of BMIPP for clinical diagnosis of ACS and intermediate likelihood of ACS was 73 percent and the specificity was 63 percent. Compared with the initial diagnosis alone, the addition of BMIPP increased sensitivity from 43 to 81 percent whereas specificity was unchanged (61 to 62 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A testing strategy is proposed based upon the available clinical evidence and a comparison of the strengths and weaknesses of available noninvasive imaging modalities for ACS assessment shown in the table (",
"    <a class=\"graphic graphic_table graphicRef74994 \" href=\"UTD.htm?41/17/42268\">",
"     table 5",
"    </a>",
"    ). In addition to published evidence, local availability, expertise and experience influence selection of the appropriate imaging modality to aid clinical decision-making.",
"   </p>",
"   <p>",
"    We recommend the following diagnostic protocol for ED patients presenting with possible ACS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial assessment including history, physical examination, ECG, and troponin levels are used to determine the likelihood of ACS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial evaluation and its limitations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chest pain and intermediate to high risk features (",
"      <a class=\"graphic graphic_table graphicRef65662 \" href=\"UTD.htm?19/21/19805\">",
"       table 2",
"      </a>",
"      ) such as dynamic ischemic ECG changes or elevated cardiac biomarkers, such as troponins, are likely to be having an ACS event and thus noninvasive imaging for triage purposes is unnecessary. These patients require hospital admission and usually undergo early cardiac catheterization, followed by coronary revascularization, if appropriate. In such patients, noninvasive testing will not alter the proposed triage and treatment strategy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"       \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"       \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with low-to-intermediate probability of ACS (",
"      <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"       table 1",
"      </a>",
"      ) with low risk features (",
"      <a class=\"graphic graphic_table graphicRef65662 \" href=\"UTD.htm?19/21/19805\">",
"       table 2",
"      </a>",
"      ), no prior history of myocardial infarction, negative cardiac biomarkers, and ECG without evidence of ischemia, with ongoing or recent chest pain (or equivalent) are suitable candidates for assessment by noninvasive rest imaging. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rest myocardial perfusion imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Rest two-dimensional echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with ongoing chest pain, we recommend either injection with radioactive isotope for rMPI or rest 2D-echocardiography. For rest echocardiography, intravenous ultrasonic contrast agent should be used to optimize endocardial border detection if all segments are not well visualized.",
"     </li>",
"     <li>",
"      For patients who present within two hours of symptoms, we recommend rest radionuclide myocardial perfusion imaging (rMPI).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with possible ACS with prior myocardial infarction may have chronic abnormalities on resting imaging (rMPI and echocardiography), which, unless prior imaging is available for comparison, would make the interpretation of the resting images difficult. For these patients, if serial troponins are negative and dynamic ECG changes are not present after six to eight hours of observation, we recommend provocative stress testing with imaging (either rMPI or echocardiography depending on local availability and expertise).",
"     </li>",
"     <li>",
"      Stress testing is recommended for low risk patients (",
"      <a class=\"graphic graphic_table graphicRef65662 \" href=\"UTD.htm?19/21/19805\">",
"       table 2",
"      </a>",
"      ) with suspected ACS without recurrent ischemic discomfort after at least six to eight hours of observation if follow-up 12 lead ECG is normal or unchanged from previous tracings and two troponin levels at least six hours apart are normal. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Stress testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with the above characteristic with an ECG that is interpretable for ischemic changes should undergo exercise ECG test, given its wide availability, low risk and cost. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Exercise ECG stress test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who can exercise should undergo exercise stress testing over pharmacological stress testing so that information on functional capacity can be obtained. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Choice of stress test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are unable to exercise should undergo pharmacologic stress testing combined with imaging (vasodilator stress rMPI or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography).",
"     </li>",
"     <li>",
"      Patients who have an uninterpretable ECG for ischemia (eg, LBBB, ventricular paced rhythm, LVH with strain pattern, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      therapy) should undergo stress testing with imaging (either rMPI or echocardiography). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Stress imaging tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inpatient early stress testing is generally preferred to outpatient testing. However, outpatient stress testing is a reasonable alternative for appropriately screened patients with low probability of ACS due to CAD (",
"      <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"       table 1",
"      </a>",
"      ) who are compliant and reliable and have proper instructions with close follow-up with an outpatient stress test scheduled to be performed within 72 hours of ED discharge. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Inpatient or outpatient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a low-to-intermediate probability of ACS due to CAD (",
"      <a class=\"graphic graphic_table graphicRef51033 \" href=\"UTD.htm?34/58/35756\">",
"       table 1",
"      </a>",
"      ) who have no history of CAD or MI and who are symptom-free may be candidates for CCTA if they have normal renal function and are able to cooperate by lying still and holding their breath. Incorporating CCTA into an early evaluation strategy in patients presenting with suspected ACS may facilitate triage decisions and shorten lengths of stay. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Coronary computed tomographic angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMR is not recommended for routine risk stratification of possible ACS at this time. However, CMR may be helpful to establish a diagnosis in individual cases (eg, for suspected myocarditis). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cardiovascular magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation that may include cardiology consultation and coronary angiography is recommended in patients with stress or imaging that reveals ongoing or inducible ischemia, significant coronary artery stenosis, or indeterminate results. Consultation may also be considered for patients with a known history of coronary artery disease as their tests are more difficult to interpret. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=see_link&amp;anchor=H23#H23\">",
"       \"Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome\", section on 'Consultations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A low risk patient (",
"      <a class=\"graphic graphic_table graphicRef65662 \" href=\"UTD.htm?19/21/19805\">",
"       table 2",
"      </a>",
"      ) with a negative diagnostic test (rest or stress test as recommended above) can be managed as an outpatient if clinically stable. Appropriate instructions for activity, medications, and follow-up should be provided to discharged patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=see_link&amp;anchor=H24#H24\">",
"       \"Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome\", section on 'Final disposition'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/1\">",
"      Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/2\">",
"      Gallagher MJ, Ross MA, Raff GL, et al. The diagnostic accuracy of 64-slice computed tomography coronary angiography compared with stress nuclear imaging in emergency department low-risk chest pain patients. Ann Emerg Med 2007; 49:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/3\">",
"      Lee TH, Cook EF, Weisberg M, et al. Acute chest pain in the emergency room. Identification and examination of low-risk patients. Arch Intern Med 1985; 145:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/4\">",
"      Rude RE, Poole WK, Muller JE, et al. Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patients. Am J Cardiol 1983; 52:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/5\">",
"      Sanchis J, Bod&iacute; V, N&uacute;&ntilde;ez J, et al. Limitations of clinical history for evaluation of patients with acute chest pain, non-diagnostic electrocardiogram, and normal troponin. Am J Cardiol 2008; 101:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/6\">",
"      Turnipseed SD, Trythall WS, Diercks DB, et al. Frequency of acute coronary syndrome in patients with normal electrocardiogram performed during presence or absence of chest pain. Acad Emerg Med 2009; 16:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/7\">",
"      Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/8\">",
"      Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation 1998; 98:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/9\">",
"      Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation 1999; 99:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/10\">",
"      Nesto RW, Kowalchuk GJ. The ischemic cascade: temporal sequence of hemodynamic, electrocardiographic and symptomatic expressions of ischemia. Am J Cardiol 1987; 59:23C.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/11\">",
"      Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003; 108:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/12\">",
"      Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. Circulation 2009; 119:e561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/13\">",
"      Udelson JE, Beshansky JR, Ballin DS, et al. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. JAMA 2002; 288:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/14\">",
"      Stowers SA, Eisenstein EL, Th Wackers FJ, et al. An economic analysis of an aggressive diagnostic strategy with single photon emission computed tomography myocardial perfusion imaging and early exercise stress testing in emergency department patients who present with chest pain but nondiagnostic electrocardiograms: results from a randomized trial. Ann Emerg Med 2000; 35:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/15\">",
"      Kontos MC, Haney A, Ornato JP, et al. Value of simultaneous functional assessment in association with acute rest perfusion imaging for predicting short- and long-term outcomes in emergency department patients with chest pain. J Nucl Cardiol 2008; 15:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/16\">",
"      Wackers FJ, Brown KA, Heller GV, et al. American Society of Nuclear Cardiology position statement on radionuclide imaging in patients with suspected acute ischemic syndromes in the emergency department or chest pain center. J Nucl Cardiol 2002; 9:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/17\">",
"      Fram DB, Azar RR, Ahlberg AW, et al. Duration of abnormal SPECT myocardial perfusion imaging following resolution of acute ischemia: an angioplasty model. J Am Coll Cardiol 2003; 41:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/18\">",
"      Wackers FJ, Sokole EB, Samson G, et al. Value and limitations of thallium-201 scintigraphy in the acute phase of myocardial infarction. N Engl J Med 1976; 295:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/19\">",
"      Bilodeau L, Th&eacute;roux P, Gr&eacute;goire J, et al. Technetium-99m sestamibi tomography in patients with spontaneous chest pain: correlations with clinical, electrocardiographic and angiographic findings. J Am Coll Cardiol 1991; 18:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/20\">",
"      Varetto T, Cantalupi D, Altieri A, Orlandi C. Emergency room technetium-99m sestamibi imaging to rule out acute myocardial ischemic events in patients with nondiagnostic electrocardiograms. J Am Coll Cardiol 1993; 22:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/21\">",
"      Fesmire FM, Hughes AD, Stout PK, et al. Selective dual nuclear scanning in low-risk patients with chest pain to reliably identify and exclude acute coronary syndromes. Ann Emerg Med 2001; 38:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/22\">",
"      Conti A, Gallini C, Costanzo E, et al. Early detection of myocardial ischaemia in the emergency department by rest or exercise (99m)Tc tracer myocardial SPET in patients with chest pain and non-diagnostic ECG. Eur J Nucl Med 2001; 28:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/23\">",
"      Peels CH, Visser CA, Kupper AJ, et al. Usefulness of two-dimensional echocardiography for immediate detection of myocardial ischemia in the emergency room. Am J Cardiol 1990; 65:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/24\">",
"      Sasaki H, Charuzi Y, Beeder C, et al. Utility of echocardiography for the early assessment of patients with nondiagnostic chest pain. Am Heart J 1986; 112:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/25\">",
"      Sabia P, Afrookteh A, Touchstone DA, et al. Value of regional wall motion abnormality in the emergency room diagnosis of acute myocardial infarction. A prospective study using two-dimensional echocardiography. Circulation 1991; 84:I85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/26\">",
"      Kontos MC, Arrowood JA, Paulsen WH, Nixon JV. Early echocardiography can predict cardiac events in emergency department patients with chest pain. Ann Emerg Med 1998; 31:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/27\">",
"      Lewis WR. Echocardiography in the evaluation of patients in chest pain units. Cardiol Clin 2005; 23:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/28\">",
"      Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997; 95:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/29\">",
"      Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol 2007; 50:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/30\">",
"      Lim SH, Sayre MR, Gibler WB. 2-D echocardiography prediction of adverse events in ED patients with chest pain. Am J Emerg Med 2003; 21:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/31\">",
"      Paventi S, Parafati MA, Luzio ED, Pellegrino CA. Usefulness of two-dimensional echocardiography and myocardial perfusion imaging for immediate evaluation of chest pain in the emergency department. Resuscitation 2001; 49:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/32\">",
"      Goldstein JA, Gallagher MJ, O'Neill WW, et al. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. J Am Coll Cardiol 2007; 49:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/33\">",
"      Goldstein JA, Chinnaiyan KM, Abidov A, et al. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. J Am Coll Cardiol 2011; 58:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/34\">",
"      Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. N Engl J Med 2012; 366:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/35\">",
"      Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med 2012; 367:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/36\">",
"      Hulten E, Pickett C, Bittencourt MS, et al. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. J Am Coll Cardiol 2013; 61:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/37\">",
"      Takakuwa KM, Keith SW, Estepa AT, Shofer FS. A meta-analysis of 64-section coronary CT angiography findings for predicting 30-day major adverse cardiac events in patients presenting with symptoms suggestive of acute coronary syndrome. Acad Radiol 2011; 18:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/38\">",
"      Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57:e215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/39\">",
"      Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation 2010; 122:e525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/40\">",
"      Georgiou D, Budoff MJ, Kaufer E, et al. Screening patients with chest pain in the emergency department using electron beam tomography: a follow-up study. J Am Coll Cardiol 2001; 38:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/41\">",
"      Laudon DA, Behrenbeck TR, Wood CM, et al. Computed tomographic coronary artery calcium assessment for evaluating chest pain in the emergency department: long-term outcome of a prospective blind study. Mayo Clin Proc 2010; 85:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/42\">",
"      Nabi F, Chang SM, Pratt CM, et al. Coronary artery calcium scoring in the emergency department: identifying which patients with chest pain can be safely discharged home. Ann Emerg Med 2010; 56:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/43\">",
"      Henneman MM, Schuijf JD, Pundziute G, et al. Noninvasive evaluation with multislice computed tomography in suspected acute coronary syndrome: plaque morphology on multislice computed tomography versus coronary calcium score. J Am Coll Cardiol 2008; 52:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/44\">",
"      Rubinshtein R, Gaspar T, Halon DA, et al. Prevalence and extent of obstructive coronary artery disease in patients with zero or low calcium score undergoing 64-slice cardiac multidetector computed tomography for evaluation of a chest pain syndrome. Am J Cardiol 2007; 99:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/45\">",
"      Cheng VY, Lepor NE, Madyoon H, et al. Presence and severity of noncalcified coronary plaque on 64-slice computed tomographic coronary angiography in patients with zero and low coronary artery calcium. Am J Cardiol 2007; 99:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/46\">",
"      Schenker MP, Dorbala S, Hong EC, et al. Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: a combined positron emission tomography/computed tomography study. Circulation 2008; 117:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/47\">",
"      Kwong RY, Schussheim AE, Rekhraj S, et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation 2003; 107:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/48\">",
"      Ingkanisorn WP, Kwong RY, Bohme NS, et al. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. J Am Coll Cardiol 2006; 47:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/49\">",
"      Cury RC, Shash K, Nagurney JT, et al. Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. Circulation 2008; 118:837.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson, JL, Adams, CD, Antman, EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on July 28, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/51\">",
"      Hermann LK, Weingart SD, Duvall WL, Henzlova MJ. The limited utility of routine cardiac stress testing in emergency department chest pain patients younger than 40 years. Ann Emerg Med 2009; 54:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/52\">",
"      Richards D, Meshkat N, Chu J, et al. Emergency department patient compliance with follow-up for outpatient exercise stress testing: a randomized controlled trial. CJEM 2007; 9:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/53\">",
"      Meyer MC, Mooney RP, Sekera AK. A critical pathway for patients with acute chest pain and low risk for short-term adverse cardiac events: role of outpatient stress testing. Ann Emerg Med 2006; 47:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/54\">",
"      Manini AF, Gisondi MA, van der Vlugt TM, Schreiber DH. Adverse cardiac events in emergency department patients with chest pain six months after a negative inpatient evaluation for acute coronary syndrome. Acad Emerg Med 2002; 9:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/55\">",
"      Stein RA, Chaitman BR, Balady GJ, et al. Safety and utility of exercise testing in emergency room chest pain centers: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 2000; 102:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/56\">",
"      Zalenski RJ, McCarren M, Roberts R, et al. An evaluation of a chest pain diagnostic protocol to exclude acute cardiac ischemia in the emergency department. Arch Intern Med 1997; 157:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/57\">",
"      Amsterdam EA, Kirk JD, Diercks DB, et al. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol 2002; 40:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/58\">",
"      Candell-Riera J, Oller-Mart&iacute;nez G, de Le&oacute;n G, et al. Yield of early rest and stress myocardial perfusion single-photon emission computed tomography and electrocardiographic exercise test in patients with atypical chest pain, nondiagnostic electrocardiogram, and negative biochemical markers in the emergency department. Am J Cardiol 2007; 99:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/59\">",
"      Fesmire FM, Hughes AD, Fody EP, et al. The Erlanger chest pain evaluation protocol: a one-year experience with serial 12-lead ECG monitoring, two-hour delta serum marker measurements, and selective nuclear stress testing to identify and exclude acute coronary syndromes. Ann Emerg Med 2002; 40:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/60\">",
"      Shoyeb A, Bokhari S, Sullivan J, et al. Value of definitive diagnostic testing in the evaluation of patients presenting to the emergency department with chest pain. Am J Cardiol 2003; 91:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/61\">",
"      Nerenberg RH, Shofer FS, Robey JL, et al. Impact of a negative prior stress test on emergency physician disposition decision in ED patients with chest pain syndromes. Am J Emerg Med 2007; 25:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/62\">",
"      Douglas PS, Khandheria B, Stainback RF, et al. ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 appropriateness criteria for stress echocardiography: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, American Society of Echocardiography, American College of Emergency Physicians, American Heart Association, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance: endorsed by the Heart Rhythm Society and the Society of Critical Care Medicine. Circulation 2008; 117:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/63\">",
"      Conti A, Sammicheli L, Gallini C, et al. Assessment of patients with low-risk chest pain in the emergency department: Head-to-head comparison of exercise stress echocardiography and exercise myocardial SPECT. Am Heart J 2005; 149:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/64\">",
"      Bholasingh R, Cornel JH, Kamp O, et al. Prognostic value of predischarge dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. J Am Coll Cardiol 2003; 41:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/65\">",
"      Nucifora G, Badano LP, Sarraf-Zadegan N, et al. Comparison of early dobutamine stress echocardiography and exercise electrocardiographic testing for management of patients presenting to the emergency department with chest pain. Am J Cardiol 2007; 100:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/66\">",
"      Miller CD, Hwang W, Hoekstra JW, et al. Stress cardiac magnetic resonance imaging with observation unit care reduces cost for patients with emergent chest pain: a randomized trial. Ann Emerg Med 2010; 56:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/67\">",
"      Miller CD, Hwang W, Case D, et al. Stress CMR imaging observation unit in the emergency department reduces 1-year medical care costs in patients with acute chest pain: a randomized study for comparison with inpatient care. JACC Cardiovasc Imaging 2011; 4:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/68\">",
"      Wang Y, Zhang Z, Kong L, et al. Dual-source CT coronary angiography in patients with atrial fibrillation: comparison with single-source CT. Eur J Radiol 2008; 68:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/69\">",
"      Rinkevich D, Kaul S, Wang XQ, et al. Regional left ventricular perfusion and function in patients presenting to the emergency department with chest pain and no ST-segment elevation. Eur Heart J 2005; 26:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/70\">",
"      Kawai Y, Tsukamoto E, Nozaki Y, et al. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 2001; 38:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/71\">",
"      Kontos MC, Dilsizian V, Weiland F, et al. Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial. J Am Coll Cardiol 2010; 56:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/56/29578/abstract/72\">",
"      Dilsizian V, Bateman TM, Bergmann SR, et al. Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 2005; 112:2169.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5307 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29578=[""].join("\n");
var outline_f28_56_29578=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION AND ITS LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RATIONALE FOR NONINVASIVE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Myocardial perfusion and function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Noninvasive coronary imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      REST IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Rest myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Choice of tracer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Timing of injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rest two-dimensional echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coronary computed tomographic angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1327802\">",
"      - Major society statements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Coronary artery calcium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      STRESS TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Patient selection and test timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Choice of stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Inpatient or outpatient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Exercise ECG stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stress imaging tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Stress myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Stress PET",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Stress CMR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPARISON OF TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SPECIAL CONSIDERATIONS FOR ED TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      INVESTIGATIONAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Myocardial contrast echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Imaging ischemic memory by (123)I-BMIPP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5307\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5307|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/58/35756\" title=\"table 1\">",
"      CHD likelihood with chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/21/19805\" title=\"table 2\">",
"      Risk death MI unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/46/29421\" title=\"table 3\">",
"      rMPI CP diag",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/30/493\" title=\"table 4\">",
"      rMPI CP prog",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/17/42268\" title=\"table 5\">",
"      Imaging ACS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3496?source=related_link\">",
"      Acute rest radionuclide myocardial perfusion imaging for the evaluation of suspected non-ST elevation acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=related_link\">",
"      Contrast echocardiography: Contrast agents, safety, and imaging technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20090?source=related_link\">",
"      Evaluation of chest pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31961?source=related_link\">",
"      Evaluation of patients with chest pain at low or intermediate risk for acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14376?source=related_link\">",
"      Radiation dose and risk of malignancy from cardiovascular imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11369?source=related_link\">",
"      Role of echocardiography in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_56_29579="Evaluation for neurosyphilis";
var content_f28_56_29579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation for neurosyphilis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Perform CSF evaluation if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient has clinical evidence of neurologic involvement with syphilis (eg, cognitive dysfunction, motor or sensory deficits, ophthalmic or auditory symptoms, cranial nerve palsies or symptoms or signs and meningitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of active tertiary syphilis (eg, aortitis, gumma, and iritis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No single test can be used to diagnose all cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A reactive CSF-VDRL (without substantial blood contamination) is considered diagnostic of neurosyphilis regardless of signs or symptoms. BUT it may be none-reactive when neurosyphilis is present. (Sensitivity = 50 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CSF leukocyte count usually is elevated (&gt;5 WBCs/mm",
"        <sup>",
"         3",
"        </sup>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CSF-FTA-ABS is less specific (more false-positive results) but highly sensitive. If negative, some experts believe this excludes neurosyphilis. Test difficult to obtain.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Rompalo AM. Neurosyphilis. In: Johnson R, Griffin J, McArthur J (Eds), Current Therapy and Neurology Disease, Mosby, Inc. New York, 2001. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29579=[""].join("\n");
var outline_f28_56_29579=null;
var title_f28_56_29580="Characteristics US postacute rehab settings";
var content_f28_56_29580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of US postacute care settings where rehabilitation may be provided",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Rehabilitation site",
"       </td>",
"       <td class=\"subtitle1\">",
"        Facility characteristics",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medical coverage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapy services",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nursing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Insurance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inpatient rehabilitation (acute)",
"       </td>",
"       <td>",
"        Multidisciplinary team patient care conferences required within four days of admission and weekly thereafter",
"       </td>",
"       <td>",
"        Physician available 24 hours/day, 7 days/week; active medical problem(s) requiring physician supervision with visit five or more days/week",
"       </td>",
"       <td>",
"        PT, OT, and speech therapy available. Patients must need two or more therapy services and must receive therapy three or more hours per day, five days per week.",
"       </td>",
"       <td>",
"        24-hour care",
"       </td>",
"       <td>",
"        Medicare Part A: days 1 to 20: 100 percent; days 21 to 100: 80 percent plus co-payment; &gt;100 days: no coverage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skilled nursing facility (subacute/transitional care unit)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Physician supervised; physician evaluation within two weeks of admission and every 30 days; physician available in emergencies",
"       </td>",
"       <td>",
"        PT and OT available; typically one or more session per day",
"       </td>",
"       <td>",
"        24-hour care",
"       </td>",
"       <td>",
"        Same as inpatient rehabilitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long-term acute care hospital (LTACH)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Physician available 24 hours/day; active/ongoing medical condition requiring physician-level care (eg, ventilator dependent)",
"       </td>",
"       <td>",
"        PT and OT available",
"       </td>",
"       <td>",
"        24-hour care",
"       </td>",
"       <td>",
"        Same as inpatient rehabilitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Home therapy/nursing",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Physician referral and recertification every 60 days",
"       </td>",
"       <td>",
"        PT, OT, and speech therapy available",
"       </td>",
"       <td>",
"        Home health nursing",
"       </td>",
"       <td>",
"        Typically one to three visits per week by OT/PT for one to three weeks, one visit per week with RN, daily home health aid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Outpatient (hospital or free-standing clinic)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Physician referral and recertification every 30 days",
"       </td>",
"       <td>",
"        PT, OT, and speech therapy available",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        May be limitations in number of visits per year",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     OT: occupational therapy; PT: physical therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine, 7th ed, Pacala JT, Sullivan GM (Eds), American Geriatrics Society, New York, 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29580=[""].join("\n");
var outline_f28_56_29580=null;
var title_f28_56_29581="Aspirin and CVD USPSTF rec";
var content_f28_56_29581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Aspirin for the prevention of cardiovascular disease: Clinical summary of U.S. Preventive Services Task Force recommendation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Grade: A",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Grade: D",
"       </td>",
"       <td class=\"subtitle2\">",
"        Grade: I (insufficient evidence)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Men age 45 to 79 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        Women age 55 to 79 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        Men age &lt;45 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        Women age &lt;55 years",
"       </td>",
"       <td class=\"subtitle3\">",
"        Men and women age &ge;80 years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        Encourage aspirin use when potential CVD benefit (MIs prevented) outweighs potential harm of GI hemorrhage",
"       </td>",
"       <td class=\"centered\">",
"        Encourage aspirin use when potential CVD benefit (strokes prevented) outweighs potential harm of GI hemorrhage",
"       </td>",
"       <td class=\"centered\">",
"        Do not encourage aspirin use for MI prevention",
"       </td>",
"       <td class=\"centered\">",
"        Do not encourage aspirin use for stroke prevention",
"       </td>",
"       <td class=\"centered\">",
"        No recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        How to use this recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <p>",
"         Shared decision making is strongly encouraged with individuals whose risk is close to (either above or below) the estimates of 10-year risk levels indicated below. As the potential CVD benefit increases above harms, the recommendation to take aspirin should become stronger.",
"        </p>",
"        To determine whether the potential benefit of MIs prevented (men) and strokes prevented (women) outweighs the potential harm of increased GI hemorrhage, both 10-year CVD risk and age must be considered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Risk level at which CVD events prevented (benefit) exceeds GI harms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"3\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         Age",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         10-year CHD risk",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         Age",
"        </strong>",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        <strong>",
"         10-year stroke risk",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        45 to 59 years",
"       </td>",
"       <td class=\"centered\">",
"        &ge;4 percent",
"       </td>",
"       <td class=\"centered\">",
"        55 to 59 years",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        &ge;3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        60 to 69 years",
"       </td>",
"       <td class=\"centered\">",
"        &ge;9 percent",
"       </td>",
"       <td class=\"centered\">",
"        60 to 69 years",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        &ge;8 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        70 to 79 years",
"       </td>",
"       <td class=\"centered\">",
"        &ge;12 percent",
"       </td>",
"       <td class=\"centered\">",
"        70 to 79 years",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        &ge;11 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <p>",
"         <strong>",
"          The table above applies to adults who are not taking NSAIDs and who do not have upper GI pain or a history of GI ulcers.",
"         </strong>",
"         NSAID use and history of GI ulcers increase the risk for serious GI bleeding events considerably and should be considered in determining the balance of benefits and harms.",
"        </p>",
"        NSAID use combined with aspirin use approximately quadruples the risk for serious GI bleeding events compared with the risk with aspirin alone. The rate of serious bleeding in aspirin users is approximately two to three times greater in patients with a history of GI ulcers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Risk assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <p>",
"         <strong>",
"          For men:",
"         </strong>",
"         Risk factors for CHD include age, diabetes, total cholesterol level, HDL cholesterol level, blood pressure, and smoking",
"         <br/>",
"         <strong>",
"          CHD risk estimation tool:",
"         </strong>",
"         file://healthlink.mcw.edu/article/923521437.html",
"        </p>",
"        <strong>",
"         For women:",
"        </strong>",
"        Risk factors for ischemic stroke include age, high blood pressure, diabetes, smoking, history of CVD, atrial fibrillation, and left ventricular hypertrophy",
"        <br/>",
"        <strong>",
"         Stroke risk estimation tool:",
"        </strong>",
"        www.westernstroke.org/PersonalStrokeRisk1.xls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"5\">",
"        Relevant recommendations from the USPSTF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        The USPSTF has made recommendations on screening for abdominal aortic aneurysm, carotid artery stenosis, CHD, high blood pressure, lipid disorders, and peripheral arterial disease. These recommendations are available at www.preventiveservices.ahrq.gov.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CHD: coronary heart disease; CVD: cardiovascular disease; GI: gastrointestinal; HDL: high-density lipoprotein; MI: myocardial infarction; NSAID: nonsteroidal antiinflammatory drug; USPSTF: U.S.&nbsp; Preventive Services Task Force.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: U.S. Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009; 150:396. Copyright &copy; 2009 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29581=[""].join("\n");
var outline_f28_56_29581=null;
var title_f28_56_29582="Gastric large cell lymphoma II";
var content_f28_56_29582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 216px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADYAakDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5mHSlpB0patEhRRS1QBRRS0xCUtJS1SAKKKWmISloopgFLRR9KYgHBzRRRQAUUtFMBKWiigAFLikxS0xCdqXFGKBQAUUUUAGKKWigBKWiigQUUUtACUUtFMAooooAKO9FLQAn8qKKUUCEopaBQO4lJTsUlIBKKWigBKKWkoAKSlopAJSHpTqSkO4ho/KloxSAgHQUtA6UtYo0CiiiqEFLRRTABRS0dqpCCiilpiEpaKKYBRS0uKYXExRS0dqBAKKBRQAYoxS0UAJS0UUxBRRRQAUUtFMBKWiigAoopSKAEopRRigQYoxS0fhQFxKKXpRQAUYopaBCdqKWigBMUYpaMUBcSjvS0YoAQikxTqTFIBMUYpcUUDG0Y46U7FJQFxKTFOAoNIdxlLijFLQBXHSloHSisEaBRS0VQBS0lLVIQUUYpaYgFL3ooApgFL3oFLigQlLVm3sbu5Utb2s0q/3lQkfnT7nTL61jElxZzxxn+JkOPzqHVgna6uX7ObV7OxTopSpBwQQaStDMKKKWmAmKKWigBKWlooASilopiEopTS0AJ6UpopaAEo7UuKMUhBRS4oxQAlFLQB60AJiinYoAoFcTFGKXbijFMLiUYpccUUAJRS4ooABSUuKUUAJikp2KCOaBXG0lOxRikO42kIp2KMUDuJ0pO1OxR2pBcZilxS4owaAuVR0pRSDoKWsUbBRS0CqEFL2xRTsUxDcUoFL9aAKYrhS4pyIzsFUFmPQAZNdt4T+HOq62VmuQbCz/AOekg+Y/RawxGLo4WHPWkkjfD4ariZclKN2cfY2dxfXcVtZwvNcSHakaDJJr3Pwd8I7SwsVu/Ew829OGEAb5Ix6H1NdF4b0TRfB9tnTIlN1jElxIcufx7fSjX/Epli/cvyRzzXxmY57Wxj9lhbxj36v/ACR9hlXDc1JSqK7/AARsq9jb2hshFBFAOiqoHFVmtLa6BiSNJIl4CnkCue0GNtUKySygqMkkjgkfw/Wu18OW6FSUTywT0968Cpek9XqfQYrDU8PFrqjxvxd4Gt7+S9n0rbFLChcoW4yoyVFeRspBIIwRX1L4s0Rob+4u4SVE3DxjhW9T9a8T8b+FHtS9/YDdD1kjHVff6V9lkeZqcVTqS9P8j4fN8Dr7akvX/M4ailxRivqLnz4UCjpR+lMQd6WlFFMBKKXFL3oENxS0pFLilcBtLjNOxV7RtMn1XUIrS1HzueWI4Qd2PtUymoRcpPRDjFyajHdlFULMFUEsegHetG10TU7pS0FhcyKOpCHFe9+Bfh/plta+dEi3DBfmmccsfUegrt/D+jwWEsjyqrZOQuMAV8viuJoU21Sjf1Pdo5LdXqy17I+XY/BviCQIY9LnbcMjGP8AGnHwT4jEZk/si5KDqQAa+uWktom+WJFI7AU77WhQAquPTFef/rXW6QX4/wCZ0f2LS8/w/wAj4tvNLvrIgXdnPDnpvQjNVvKf+4//AHya+zbq2tbsET28Mg7AqDVKfwvpM00UsUCRv0O0cGtocWr7dP8AH/gEPIofztfK/wCp8i2llc3kojtbeaeQ/wAMaFj+ld34N+FOv+IrkrPA+nW4GTJOhBP0FfUugaTY6dGWihhEp5YqgBrXEoCnhFz1wO1YYriurKNqMVHz3f8AkYRy2lTl7z5vwX+Z80eKfgRqWmaZJd6XfC+ePrC0e1m/3ea8du7Wa0uJILqJ4Z0OGjkXDD8K/QCJkZsMAR6GuW8ffDnRfGlk8dzGsF4B+6uY1+ZD2z6j2p5bxNVT5cT7y79V/n+ZliMHTl8C5X+B8RUmK3PGHhy+8La9daTqkey4gPDDo69mHsRWJX3FOpGpFSi7pnjyi4uzEoxS0VoIQDFLRS/WgQmKKXFBoAQ80rkM3ChRjGBRSUhiYopaD0OKAExRQvTmjNIBKXFGaWk0BSHSpRbylA3lvsPQ44NRr0Fe3fCvUNNuvDkNkVgkvbfcWidAWYE5yM152OxUsJS9pGPMejhMPHEVORyseJEEcEEfUUv0r6J1HSLS/uQZNKtzjgDYFwPqKzLj4b6FdkyNDPCxHSNsDP415keIaS0qRa/E9GeR1LXhK54TT0Rn+4rN2+UZr2mL4f6Dp8TXFxbzzxR/MfNlwB+QrW0zVdM0WcQwabbLE2GXZHnA9cmrnn0LfuYOX4FUOH61R2lK39fI8d0nwhr+rbTY6VcyI3Ryu0fma7bRfg3qU5DaxfW9iv8AcX52/wAK9Ql8SPJGotQcd+wFZ9zqV3IVMsscIPQ4Jrx62f4yrpBKH4v+vke7h+E4J3qu/wDXkWvDPhXw94VTdZxrcXf8VxMAzZ9vT8Kl1PXxHIw3qPXFc1qN4qRuxmkkYdT0FZKTW8gZ3kcTqRgYyCD/ACrynQniJOrWk5M+mwmWUMNGyWnoP1nUb7UJWWFVgQHhjyTWdZaHfahdJGLgsW6Y71qwukhO1CD6+tadkskUsckQC4IwwHeuxVXRjywSR2SkrWX/AADc0ET2se2dFuQwC7mXG3HpjpXXaYY4UCwkAE556iuasGmklaMkoG++B0zWvDDLE37tsn3rwsRLmlqeRjEpt30Oh1S2FzYnI3HHTrXlHiayWyQl2Ux5xiT+Wa9TsJpBy4x61V1fRLDUIpRNGrbx8wPIPvVYPEuhK72PFcVZ05/I+Ydd8MK7vPphGD8xizx+BrkWRkYq4KsDgg17z4g8CrFcSPZM3ln+FGwF+lchP4JuLhjG8jKT03x5r7jB53T5ffldfieZX4brVffoJfeeaYoxXZ6h4B1G3XdFNDJzgKQVNY58La1l8WE52ckhePwNetDMsNNXjNHlVMix1J2lTf5/kYoBx0OPpS4rbbRdVtY/LmspI++WFVJoLkMFe0dieAVQ81UcbCW35kTyivBXkmvkzPApcVqf2VqLx5XS58euw0618OavdzCOGymVu+8bQPfJp/XqS1k7fNErKMVL4YN/J/5GdbwPPKEiXc56CtqDRFeNQZD5mfmwufyrt/Cnw/gMyrf3UzSn7/kjauPTJ/nXs+g+G9IsbdUhtolIxg4yc/U14OYcQU4PlpanqUcgqUFzYlWfbc+dtN8CXOoFZIpJktgfnkKc/gO9ex+FvCNvpelyQWNiyGVQJJZDl5Mfy+ld8LW2iZSqAkHPTFOa5CZA49K+axmdV8SuVuy7HpYfCUaD5qcde5n2YGm2WJDsRRjFJFqUcyMyOrDOOOtVdUmMoKtkq1VLK3WHckK4yc5968qcudcz3PVp0IcnNLc0pJSwzj5hzk1Ue6kJAB4FIzvuwy9feoWmjgVzLg8cEnGKmKubQprtcu+c2PlPvVm2nbgvwc+tZ1mVlhidJFYSDcMHtU9yriPCA5PpSlHWxnOCvymxHqDDjdxUseovM5A6DpXEWepyS6i9qykMp79a6m14HPFKrTcNzLEYNUviWp0FjfFWAJ5rYF2MfK3NcojFen51fgm3Haf/ANdZxk4s8ith03dHmn7RukNrfhyLU4LZGudPbLyKPmMR4IPrg818ynpX3S9tHdqyyKGjIIKnkN9a+cfi/wDC6Tw2JdY0oPJpjuTJHjmDJ4x6r/Kvt+Gs3jGKwdZ6391+vT/I8XMcHf8AeU+m6/U8joNOI7CkxX26PDDGaO9FFMQUUUtACUlLRigBKDTutNIoAYc59qQmlNV5wwIYZxUylyq5pGNyYU7ioYX3j3FTUJ31QmrMqr0FdZ8M7yCz8YWb3JCo+Y9xOACelcovQU9SQQQSCOQRXNWpKtSlTfVWOilUdKoproz69t41KjZhvUgdBSToqq29gM9Ca4j4XeJrjV/Dw+2q8txE3lZXq4A6mtrVtTNrcC3BP2iRRsTqf/11+ZYjDTpV5UZbo/QMI/bU41E9GXr/AOzS23lSJw3GT0P/ANaqWmabbCbcyo2eAD29qmstH1C6jD6vdCKLO4RRgZH1NbFrp1rGQY5HAU8fNms3U9nFxi7nXzRitGQ/2XBj/VcntjpVW5s4j+7ZGLHjJXpWjqMxsnicDzI3OGA602O6tBbytdOVfGUXpWMJSeo1Wmveu2cvqWjedBICxTYM+hPtXM/2dbQ3DSM5hjJ+ZiuR+FdDd39ze3rGKIkHPJHJH0qKe2WaDypk/d4zsz0+pr0KdSdNcsmexQrOS95mHqmq2elqn2SQToy7sMu1lP8AWpdPvhqMPybVMeAVX+tSRaVp32lZAhyOCcZP4VqWujxRMJoColJzwOCK3qVaUY7O/ccZqLacro7rw1ZQGwW4d1kkzgxlsEe9a4jgkUPErKf7rD+VcnoWomzlZH4ZuCCOGFbgvl3ARqQT0A7V4tWF2eBiqNT2jZs7I4oGy3zY4qlfKJpdtsx8vA3EjGT3pYBIyl5VJXt9akyPmKjBrBu2iOKK5He92Ngso0TlFJx371RltYzN9wHng46VfM746YojbJHpQpW2LjOcbtlRvDlvqCkFFDe/FYWoaOltgRMxUdgc4rqpuQCDVQw5ck9D61rGq11N6GKqxestOxyVppq3hkR0kwP4iOPzqRfC0MbCTJyD6V1MVu0W7Y5VGOSvY1YdFdByPfFaPEyWx0SzCon7r0OZi0KA5Mis/t6VNHotsMkRBifWuljtwF4HWpY7dcjIAHasXiJHPLHz7mJbWCR/8sgv4dK0FhKqQOnbHathLVGAGOahEISVo26g9qlyb3OOWK53qZ7QOvBye+TWTdNIjEDlq6edA6Er/COc8Vi3ES+YSTyPTpUqWuprh6t3qZkavJtLglvT0q3Db7BnbnPWpRGAAepNWoiUIyAcUSlc3nVb2H2+iPeafczgqiQDJ3cZ79a5HUNFa7tXYllS4GUY9VAJHHpXaT3RktxFHuWPHzqDw59SKomGRkxkkA5we1awqKFnHcjDYmrSbk31/r8ThtOtrrQ5QI5DJGePm7Zrp7a4WdB/Ce+amu9PkljPlgBvU1hzQ3NnMrsjkDsRxWspqtq9z0ZVI4vVtcxr/Y4hN5yIu89WxyauRkgcVXsrtJEXcjKxGMYqzCUkDBCMjqOhBrKUW9ziqOW0uhajzsHBNN+1eVLhTlj2pEkAjJ6fWuZ8T37WBimi2vk4IB5xRCi5OyIoUHXnydzvdOuC/APT2q7qFpHe2ssF0Fkt5EKOrDIKkc1xfhbWUvIVYkJJ/dJ612aXCtEAeRjkfWpcXB26o83GYedGpZo+JfFuknQ/Eeoac3SCZlQ+q9R+lZBGa9c/aE8OS2PiVdXhQm0ukCMQPuOPX6ivJSK/WstxKxWFhVvq1r69fxPj8ZS9lWlFLTp6DfpRilFGK9A5RPrRinUUCG4pSPypaMGgBuOKCKdijigCIimEcVYK5FN2UikyEJinYFSbDTttAOVygv3RSikX7opazWxqz074Qa6+nzPbvDJ5IJcSpnqexr0jSSmo+NnvZVUpFH+7X0PrXkdl4j07SdKggsfMkl24fC4Ge/1rpfDvj3SY0SOWOWG4dsNI3IAr43M8BWrVJ16dN66f8E+ry3MKVGmqM5nqOozz3MuyI7RnOc1TLXSzpEhOW6ntTbbXdNuoFk+0QDPLbW6fSq8/iOxt5W2SGQAHhBuavn40Z/Co6+h7scXGC1tY09Te5jiWJcSlF3Ng9CT0rltQvr1Fl/0dcnhQOTmop/HllHFL5ETGQ8Evzg/SuBv9daO4lvDey+bKSSu7k/h2r0cFltaT96Njjr5rRp6p3OytNVltLy9t7yfAUhzIzY28dK5bVvGkgaVbZlwcgFec/WuLv9SmvZWaV2IPYmqW/GccV9Lh8lpxfPV1Z4WJ4hrSXJQ91fiXZ9XvpZ/NN3Mr5yNrkYrR0LxZqmkTK0Ny8sWctFKdyn/CueJ5pRXqywtGUeSUU16HjRxdaMudTd/U9y0f4gaJqIjjmZ7O4PGJR8uf96u003Vbfz0jLbgwyGU5H518tg1uaF4k1DR5VNvMxQcbG5GPSvnMZw1TacsO7Psz6HCcSztyYpXXdbn2JbTiazSPcCijIz3pfsbD5gQc15B4T+I7NBFNcQboDwwTnH4dq9U8P+J9L1WESWd1Ew/iUnlfwr47FYGtQlapHY7vaJrmou6ZYkt2AyB9eKbFFgfd5rajaKdDtIbd3FRvboCdx7Vx8j6ErEPZmdHFuzkAfWq8y4kAXGKvSRqA3zYH1rOkCK2S5DA5UdiKfIzam+ZkxjDD29aWCBBwB1NVvtaJxuyauQyYCvkfMM8GolFlSUoosPGq4FSgRiPczYI4AxzTBIGbAwfpViHy2++ML/EfSpUdTlk2lqU5JWPfHsKIBhieSO5NOnaJ5SYgfKU9SetQlmeQhMiqeholddguDuJ2mqqW+8461peQFQYFEcfOOlRdjVXlWhmy2RjUuuSMd+1FpbZ5fkmugtizRzIgTYVyxPbFULaJuBj3psFiJNNMryWuMbR27VPBbFlCkYNXHiO1TtPB61o2toEUyP39etNRbZz1MTaJmpaCIFmUe2awvF99a21qZbhkSJeTk4FanizUUsIGJkUHaScnoPU18s/EjxjJrV3La28zvaqxBbPD/wD1q9TK8srY+ryw0it2CxEMNBYis/RdX/Xc9VtviDoCXgtxdJuHGccV1FrquiamoEV0nnEZDKcGvkYOw+6dp9a2NG1V7YgtMwK+9fSYnhlQjeEmTQzulWl765fQ+qZBFDbP506MvRTu5Fcxq+ky3ds09o4uEHPuteVQeILm5EZEzyJEwYebz+tegeG/iLYB0sb2IQkjIdOleLPL6+H1jqfQYfEqC9pSld3KySS6e6uBh1PDAdK6vQvFe6RYpQxBAwRzV6e1tNUtxLaGN1YZyp4IrBbR/sl6PIkaNXIBxxg1zTcKi95anoSrUMXFqrG0js72ys9fthFdxLcW0gKvG/IP/wBevnf4sfDubwfqCT2Iln0eddySkZMR7qxH6GvdtJuHsGjjYFxn53Pc11gWy1Cye01GNJreZSrI4yGBrTKs0q5dW0d4Pdf11Pks1wKqKz2WzPhkiivTfi58NpPCVyb7TA82jStwTyYD6N7ehrzTFfpuFxVPFU1VpO6Z8fWoyoy5ZDcUY5px9KMetdJiNpRTsUdqAGkUoHWlpe9IBtLilxQOlACUuKMc8UuKQGUvQU6kX7o+lOAqFsbsBTh3pvelFMRbt765txiGZ1HpUjapespU3Mm09QDiqNOAqPZxbvYOeSVrj/Nfn525689abnJz396BRV2JuIaBS4pcUxXG0uKUCigLgKUUYooC5Ytbue1bdbyvGe+Dwau2+s3cNwsyyEOOpU7c1lU4VlOjCfxI0hWnD4XY9S8O/EjUYAsUd0Ub/poeK6M/ErU3jPmXK+4QjJ+leFA09ZXHRz+deTWyLDzlzRSR6dPOKqVp6nssHiOXxTeCyGoS2V3nMSyt8kp/u5HevQtLtNcvLDyruRLWSP5dw5LD8a+XUupQwYNhhyD3FdTpXxD8SacmyG/aSP8AuyjdXm4zIKsklQtbs/8AP/M9TC8QQh/EXzt+h72uk38E25r53I6qy8GrUl7fWgRVtGm9SpxivLdL+McmxRqljucdWhPB/Cup0z4raDckC5Z4exLjpXgV8oxtN3nTv6a/kezDN8PXs3KL/D/I9B0W6nuiS0Gw+7Cn6pc3bTi2tVA3D5n6gCuVXxz4ORJJX1KPKoZMJkM3sPeuGvfjS329/wCzrHybTopkOWPua56OT4uu24U3p30/M5auOwtOpzNr+vvPeLdZVtTAVADgBj61oW1ogA6cV4JpnxY1KecKFilRjwu3n9K6R/iPqlvalo9NwTzuY8ClPKMRCXLKP4nNKcZpuE0exLbJjhgDjjNMS3CMMjIrwy3+Nk0UohubRJJF9GAqRvjHdK5ZreEITxmQAgU3kuKX2DnTi7/vEe3JCoBUHHqParKW6AZ4OK8OT4yReSWY26P6l/6VkyfHZ7WU/ZbdrlcfxAKDV0cjxk3ZU2TVnTgruoj6LAVyBncF6Vz/AIq8W6X4dspZL66jRgDwT3/xr531f46+JbtXS0jtbRWGAVXLD8a8z1nWb/WLlp9RuZJ5Cc5Y8D8K9bCcK1pyTxDUV5as8+WOpQ295/gdV8QPiHf+J7yVIXe308EhUB+Zx6sf6VwZNBNJX22HwtPDU1TpKyR5davOtLnm7sOtA60dTRXRYyua2m3sUME0Fw0ojccGPqD6fjVu3tLWV5bhbhVjSIsiM3zFh/DntXPirlncCMlWAwwwT6VwYnB815w0Z6GEx8qVoS2/I9A03X9R8Ix2rWqSSwtGJpsnIQHt9PevQ9E8d6brqxC5KwSOMc+teT6s0z6fFLbyedAluIXw33164NZegmGKZHnXdA3T5sFa+XrZdTxFNzkrS7o+qhmDhUUXqun/AAGfTcZQKu0CRccMprL1iS9t4xJaZdeuAeRXnlvdalp9qLrRruSeJAGaBvmJHfFdT4e8b2V/KLe9/cz5288DNfPywEo+8veS/rY9SlXjGSdr+TLNnr9xJC0eoKtxaSfJJDMvGPTmuM8WfDC2vzJfeFXWAEbjZyHgn/ZP9K9QuNNtL22d0ePaeTjmsSeOexsT9nkZiDkZGc1rhMdVwk+ag7eXRmmKwWEzJWcbM+c9U0270y5NvqFvLbzDja64/L1qpivpCKzsPEltJY6rAtzHnIzw6e6nqK8x8f8Aw3vPDu+80/zLzTAeTj54vZvUe9fZ5fn1HEy9lV92f4P0/wAj4rNMirYKT5feX4nnuKKcRRivfPBExRRS4oEIKO1LijHHNIYlJh/Vfyp2OxpdtILmSvIFOFNXoKUVC2NmOFLQKUCmSKKUCnAAUtOzFcbilpQcdqUt9KLCG4oxTgR3FBb2osA3FLj9KUEUuRRYBuKKdkUmRmgQlFLxSUwCiiigYtKDTaKAHg4p26o80Zp2ESb8CkLZNMozRYCRZGU7lYqfUcVI91PIMPNIw9C5NV80UWQ7j80pOOtR0pJOCadhDgaN3vTKKLASFqTNNo60xDu1HakBoosAtFBopiF70CilosA4SOE27iFPbPFTWs5iO0jKH7wNVx1pRxUyhGSs0VGbi7pnd+FNZFiRHbOzxEkBWPI96s3dp5hubwZiimJwwPIPb6VxOkzw219FLcBzGpyQvWuqO/W2im83y4DIQsO4DC+tfNYzBewq88dn1PpcFj/a0+WXxLodX4C8V3OhxhbxxPZZwdw+ZffPevYrK7sdZs1msnSVGGRtr561zwze2dvJNFcI0PyqpUnDf7w7VX8LeI7vRtXjjs5ZoD0kjkOVz3wPSvCxGAhik6tF6nuRqNcsauj6Pue/SaZ5F159uAj9/WiLUpQ5E0Q2j5Tu5BHuKb4M8T2HiS3ZWlQ3ScMF6fWt2+0pHGf4T36g14M4ShJxktUdX1iLfLWV/M848T/DrQfEUzyaY66ZfuN+V5jY+69vwrxfxT4X1Twzem31W2ZVJ+SZRmNx6g19Kvp9tHOsgYiRMqOaW7kt7qA2eoJHc2bggxyrkf8A1q9vL8/rYVqFT3o+e69GeTjslo4j3qGjPk0jNGK9a8a/C4oWvPCp82BuWtGb5k/3T3HtXllzby20zRXEbxSocMjjBB+lfcYPH0MZDnoyv5dV6nyOJwlXDS5aisQGjFOxRiuw5huOaX8aXGfwowaAMZegpwpq9BTxULY3Yo5qQUxetOzTRDHUUmaKoQtFJS0AHaikz70UALRRRQACiijNABS0lFABS0lFABS0lAoAWjNJS0CCikopgLSscnOKbmimAtLSUUALRSUtABS0naimIcOOc0tNpaBC0UUv0pgFLSUv0piDtS0AUo9qQC9DU1uxDZDEHtg1EKcpwaTVxptHqngzVre+trPSJN8k8iss27ngcg5pPHXht00t9TtkCTWr7X2/xJ2Ncf4Q1D+zdfsrrGVDbW+h4r6DOnw6zpNzaTkCO5jKbh2z0NfB5s/7Lx0KkF7ktX9+v4H22W4h47L50qm8dF3WmjPnvS/E99YTRyRMo24Py/LnHrivSfDfxknW48jWowtqekqZZlPuPSvJtf0m40TVriwu0ZZIXKgkY3Dsw9qz844r6StlODxkVO2/VHzizLFUXySd7dGe8+KPiLpeq2OzSJTHcocmRlIH0A71Ho2p6uBCbkQ3ET4JwOTmvDUfHeuq8O69eLcQWst2yxMdisR930/CvHxnDypUn7DXrrufQZTxBT51TxKsn9x7zDdBgjLGyY53gcA1R8TeENC8VWsjTnydSUYW4j657Z9RW14JuP3aW1zGskjfxjkEVNrenLp2sQXEIxDK+JAPWvjqNeph6l6bs0e1iYUq83QqLzXmfLviLR7nQ9VnsL1CksR6now7MPY1l8568V7N+0JbRF9Iu41G8h4nPsMEfzNeMniv07K8Y8bhYV5aN7+q0Pz3HYdYetKmtgA796XFJS7hXoWOQxF6CnCmr0FPWoRux1FJRTJFzSg00UtADwaWmA806miWGM0tFFMBCMiloxRQAh5FFLij60AIc44oFHaloAQ+1A6c0tFABSDpmlpKAFooopgFFFFMAoozRTEApaSjvQAtLSZooEL2paSlpoBRS0lFAh1AFH4UUxC96O1Hal7UALSikpaBC80uKQe9L+dICaGQrgV7j8KvENzeWAtZgJXiO1SOuMd68K9K09C1y+0O+jutOmMcy+vIPsR3ryc4y1Zjh3T+0tV6no5Zj3gq3M9YvdHo/wAejDNcaROWUXexkZM87OxP415Ka0de1e81zUpb7UZA878cDAUegHYVn4yK1yvBywWFhQm7tGWOxEcRXlVgrJgPzqeI8YqD+dPVsGu9o5D1/wCD/jUW2q2ml6q2UZwsUzHp/st/jXuuv2Zl81GAx95Wr4wSUqwZSQRzx2r1PRfjHqEFjb2mr232pIRt8xG2s/HGa+Ozrh+VWft8LHV7rb5o9/L805Wo1pbbM0fjkyjRLFJXDSm5O3jsFGf6V4sRXReMPE934lvFluVEcEeRFEOdoJ5+prniOK9zKMJPB4WNKpv1+ZwZniY4nEOpDYbS8+lL2xRgepr0zgMMdBTlpo6CnCoRux1BpKWgQlLRRQAtOBptFNCH5paZ0pQaYrC5pQaSlxTEGaWm4pRQIWijFFMAo/CiigBKBS0lABQaKKYCGilzSUxi0CjvRigAoooNAhaKSloAXtS96SimIdSjpSUCmIUcGlHWkFKKBC0o6UlKOlMQuaKBSjrSAUUtHSjPWgBRn8KPpQB+dLigAH0pSAMEc0CikAe1KKPel4zSABS0me9LnmkA7ORQaQDIyB0p2M0hje1OxSYpfwpAYI6UopB0pahHSLmlpKKYhwozSUCgQ6ikpaBBRRSgUwFBp1NAp1MkOaWiimIKKKKBBRRSGmMKKKKLAAoo70UAFIelLSGmMKWiigAFFFLQIKKKKYCiiiigQppRSUtAhaUdaQUtMQo60uKQGlpiFHtS0gNKKBC5pR702gUhj80tNpRzQIdRR1pM0gFxg0tN60v4UhjulAxik4zznFFIB44pw4PtUYxTuwpAKaMmk5p21vQ0rjMAdKdRRUI6WFFFFMQtFFFADhS0UUyQpaKKYhRThRRQIWiiimIKKKKaAKKKKACiiimAlFFFAwooopgFGKKKACloooEFAoooAWloopoQfypRRRQhB0NOHSiigTFGKO9FFMBRSiiigQtFFFJgKOKcKKKBMcOhpKKKAFo60UVLAKUUUUhjs0uQRRRSAD+lG5v7xoopMD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal whole mount section on a gastric large cell lymphoma with annular ulcerations and full- thickness infiltration of the gastric wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29582=[""].join("\n");
var outline_f28_56_29582=null;
var title_f28_56_29583="Mucinous cyst PI";
var content_f28_56_29583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cyst on the finger",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This person has a cyst on the finger joint nearest to the fingernail.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_56_29583=[""].join("\n");
var outline_f28_56_29583=null;
